Snijders Blok-Campeau Syndrome

Mendelian MONDO:0032600 Pathograph 38 Show in embeddings browser Neurodevelopmental disorder Chromatinopathy NuRDopathy Intellectual disability syndrome

Snijders Blok-Campeau syndrome (SNIBCPS; OMIM 618205) is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in CHD3 (chromodomain helicase DNA-binding protein 3) at chromosome 17p13.1. CHD3 encodes an ATP-dependent chromatin remodeler that is a catalytic subunit of the NuRD (Nucleosome Remodeling and Deacetylase) complex, which couples chromatin remodeling with histone deacetylation to regulate gene expression during brain development. The syndrome is characterized by global developmental delay, intellectual disability, severe speech and language impairment (including childhood apraxia of speech), macrocephaly, hypotonia, and a recognizable facial gestalt featuring frontal bossing, hypertelorism, broad nasal bridge, prominent forehead, deep-set eyes, and pointed chin. Inguinal hernias and a distinctive hypersociability/overfriendliness behavior — recapitulated in zebrafish chd3 knockouts — are additional features. SNIBCPS is grouped with CHD4-related Sifrim-Hitz-Weiss syndrome and GATAD2B-related GAND in the emerging "NuRDopathy" class of macrocephaly-associated neurodevelopmental disorders. Most pathogenic variants are de novo missense changes clustering in the catalytic ATPase/helicase domain (with a striking enrichment of arginine substitutions), but truncating variants and copy-number changes outside this domain produce an indistinguishable dominant phenotype, while rare biallelic variants cause a more severe neurocognitive syndrome. Variable expressivity has been documented, with some inherited variants present in mildly or unaffected parents. A first-in-human AAV base-editing gene therapy trial for the recurrent R1025W variant has entered Phase I (NCT06860672).

Ask OpenScientist

Ask a research question about Snijders Blok-Campeau Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE NEUROLOGIC
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
Autosomal dominant inheritance, most commonly arising de novo via heterozygous missense or truncating variants in CHD3, though inherited heterozygous variants with variable expressivity (predominantly maternally transmitted) are also documented.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:30397230 SUPPORT Human clinical
"we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein."
Establishes heterozygous de novo CHD3 variants as the primary cause of autosomal dominant Snijders Blok-Campeau syndrome.
PMID:35346573 SUPPORT Human clinical
"We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome."
Demonstrates autosomal dominant transmission with variable expressivity in multi-generational families.
⚙

Pathophysiology

3
CHD3-dependent NuRD chromatin remodeling defects
CHD3 is an ATP-dependent chromatin remodeling enzyme that uses energy from ATP hydrolysis to slide and reposition nucleosomes along DNA. It is one of three mutually exclusive catalytic subunits (CHD3, CHD4, CHD5) of the NuRD complex, which couples chromatin remodeling with histone deacetylation to regulate gene expression. Pathogenic missense variants cluster within the central ATPase/helicase domain and disrupt critical binding and interaction motifs. Functional assays show that a subset of variants directly impair ATPase activity, while nearly all yield alterations in chromatin remodeling. Both gain- and loss-of-function effects, as well as haploinsufficiency from truncating and whole-gene copy-number changes, can produce the same clinical phenotype.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
CHD3 hgnc:1918 ⚠ ABNORMAL HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves abnormal CHD3 (hgnc:1918). hgnc:1918 is a gene from the HUGO Gene Nomenclature Committee.
chromatin remodeling GO:0006338 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased chromatin remodeling (GO:0006338). GO:0006338 is a biological process from the Gene Ontology. regulation of gene expression GO:0010468 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated regulation of gene expression (GO:0010468). GO:0010468 is a biological process from the Gene Ontology.
ATP-dependent chromatin remodeler activity GO:0140658 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves abnormal ATP-dependent chromatin remodeler activity (GO:0140658). GO:0140658 is a molecular function from the Gene Ontology. chromatin binding GO:0003682 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves abnormal chromatin binding (GO:0003682). GO:0003682 is a molecular function from the Gene Ontology.
Downstream
Disrupted NuRD-dependent cortical layer specification
Disrupted BMP/Wnt signaling in cranial neural crest cell specification
Show evidence (2 references)
PMID:30397230 SUPPORT Human clinical
"Most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs."
Establishes the structural and functional impact of CHD3 missense mutations on the ATPase/helicase domain.
PMID:30397230 SUPPORT In vitro / ex vivo
"Experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling."
Demonstrates the molecular consequences of CHD3 mutations on chromatin remodeling activity.
Disrupted NuRD-dependent cortical layer specification
The Mi-2/NuRD (Nucleosome Remodeling and Deacetylase) complex couples ATP-dependent chromatin remodeling (via mutually exclusive CHD3, CHD4, or CHD5 subunits) with histone deacetylation (via HDAC1/2). During mouse cortical development a sequential subunit switch assigns non-redundant developmental roles: CHD4 drives early progenitor proliferation, CHD5 facilitates radial neuronal migration, and CHD3 is specifically required for proper cortical layer specification. Inhibition of any one CHD cannot be rescued by overexpression of another, indicating CHD3's role in the NuRD complex is irreplaceable. Loss of CHD3 catalytic function in NuRD therefore disturbs late transcriptional programs governing layer identity and post-mitotic neuronal differentiation, providing a mechanistic substrate for the intellectual disability, speech/language impairment, and structural cortical findings observed in SNIBCPS. Together with CHD4 (Sifrim-Hitz-Weiss) and GATAD2B (GAND) disorders, SNIBCPS belongs to a "NuRDopathy" class of macrocephaly-associated neurodevelopmental disorders sharing intellectual disability, hypotonia and overlapping facial features.
neural progenitor cell CL:0011020 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neural progenitor cell (CL:0011020). CL:0011020 is a cell type from the Cell Ontology. cortical projection neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cortical projection neuron, annotated with neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
CHD3 hgnc:1918 ⚠ ABNORMAL HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves abnormal CHD3 (hgnc:1918). hgnc:1918 is a gene from the HUGO Gene Nomenclature Committee.
chromatin remodeling GO:0006338 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated chromatin remodeling (GO:0006338). GO:0006338 is a biological process from the Gene Ontology. cerebral cortex development GO:0021987 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cerebral cortex development (GO:0021987). GO:0021987 is a biological process from the Gene Ontology. nervous system development GO:0007399 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal nervous system development (GO:0007399). GO:0007399 is a biological process from the Gene Ontology.
Downstream
Global developmental delay
Intellectual disability
Speech delay and impaired language
Hypotonia
Macrocephaly
Autistic features
Speech apraxia
Pain insensitivity
Seizures
Structural CNS abnormality
Show evidence (4 references)
PMID:30397230 SUPPORT Human clinical
"Chromatin remodeling is of crucial importance during brain development. Pathogenic alterations of several chromatin remodeling ATPases have been implicated in neurodevelopmental disorders."
Frames the broader rationale that disruption of chromatin remodeling ATPases like CHD3 results in neurodevelopmental disease.
PMID:27806305 SUPPORT Model organism
"Whereas CHD4 promotes the early proliferation of progenitors, CHD5 facilitates neuronal migration and CHD3 ensures proper layer specification."
In vivo mouse cortical development experiments establish that CHD3 has a specific, non-redundant role in cortical layer specification that cannot be substituted by CHD4 or CHD5, providing the developmental substrate for SNIBCPS cortical phenotypes.
PMID:27806305 SUPPORT Model organism
"Inhibition of each CHD leads to defects of neuronal differentiation and migration, which cannot be rescued by expressing heterologous CHDs."
Demonstrates the non-interchangeable function of CHD3 within NuRD and explains why CHD3 haploinsufficiency cannot be functionally compensated by paralogs.
+ 1 more reference
Disrupted BMP/Wnt signaling in cranial neural crest cell specification
During cranial neural crest cell (CNCC) specification, CHD3 is upregulated in early CNCCs and is required to enhance the BMP signalling response by opening chromatin at BMP-responsive cis-regulatory elements and by increasing expression of BMP-responsive transcription factors, including DLX paralogs. CHD3 loss in iPSC-derived CNCCs represses BMP target genes and reduces chromatin accessibility at these elements, producing an imbalance between BMP and Wnt signalling that diverts cells away from a CNCC fate toward aberrant early-mesoderm identity. Partial rescue by titrating Wnt levels demonstrates a causal role for the BMP/Wnt imbalance and points to a candidate therapeutic axis. This mechanism provides a direct molecular explanation for the recognizable craniofacial gestalt of SNIBCPS (frontal bossing, hypertelorism, broad nasal bridge, midface findings) by linking CHD3 chromatin remodeling activity to neural crest-derived craniofacial development.
cranial neural crest cell CL:0011012 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cranial neural crest cell, annotated with neural crest cell (CL:0011012). CL:0011012 is a cell type from the Cell Ontology.
CHD3 hgnc:1918 ↓ DECREASED HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased CHD3 (hgnc:1918). hgnc:1918 is a gene from the HUGO Gene Nomenclature Committee.
BMP signaling pathway GO:0030509 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased BMP signaling pathway (GO:0030509). GO:0030509 is a biological process from the Gene Ontology. neural crest cell differentiation GO:0014033 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neural crest cell differentiation (GO:0014033). GO:0014033 is a biological process from the Gene Ontology.
Downstream
Joint hypermobility
Frontal bossing
Hypertelorism
Broad nasal bridge
Deeply set eye
Narrow palpebral fissure
Sparse lateral eyebrow
Low-set ears
Full cheeks
Midface retrusion
Thin upper lip
Pointed chin
Absent teeth
Visual abnormalities
Strabismus
Hearing impairment
Inguinal hernia
Cryptorchidism
Congenital heart defects
Show evidence (3 references)
PMID:40835974 SUPPORT In vitro / ex vivo
"In control lines, CHD3 is upregulated in early stages of CNCC specification, where it enhances the BMP signalling response by opening chromatin at BMP-responsive cis-regulatory elements and by increasing expression of BMP-responsive transcription factors, including DLX paralogs."
Establishes CHD3's positive regulatory role in BMP signaling during normal cranial neural crest cell specification using human iPSC-derived models.
PMID:40835974 SUPPORT In vitro / ex vivo
"CHD3 loss leads to repression of BMP target genes and loss of chromatin accessibility at cis-regulatory elements usually bound by BMP-responsive factors, causing an imbalance between BMP and Wnt signalling. Consequently, the CNCC specification fails, replaced by aberrant early-mesoderm identity,..."
Demonstrates that CHD3 loss disrupts BMP/Wnt balance in CNCCs and identifies Wnt modulation as a potential therapeutic strategy for the craniofacial features of SNIBCPS.
PMID:40835974 SUPPORT In vitro / ex vivo
"Our findings highlight a novel role for CHD3 as a pivotal regulator of BMP signalling, essential for proper neural crest specification and craniofacial development."
Directly links CHD3 dysfunction to the craniofacial phenotype of SNIBCPS through its role in cranial neural crest specification.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Snijders Blok-Campeau Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

29
Cardiovascular 1
Congenital heart defects OCCASIONAL Abnormal heart morphology HP:0001627 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Congenital heart disease (CHD) was seen in only 5 of 24 (21%) of patients, mostly accounted for by atrial septal defects (seen in 3 patients), followed by patent ductus arteriosus (in 1 patient) and ventricular septal defect (in 1 patient)."
Congenital heart defects (CHD) occur in 14% of combined cohort patients, most commonly atrial septal defects.
Digestive 1
Inguinal hernia OCCASIONAL HP:0000023 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Inguinal hernia (HP:0000023). HP:0000023 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31737996 SUPPORT Human clinical
"CHD3 variants are associated with inguinal hernias and apraxia of speech"
Pierson et al. NuRDopathy review identifies inguinal hernia as a distinguishing feature of CHD3-related SNIBCPS that helps separate it from CHD4 and GATAD2B disorders.
PMID:32483341 SUPPORT Human clinical
"Umbilical, inguinal, and hiatal hernias, which were frequently reported in the initial patient cohort (18% of cases) ... were noted in only one of the patients presented here (4%)."
Documents pooled hernia frequency across the first (18%) and second (4%) cohorts (~12% combined), supporting OCCASIONAL frequency.
Ear 2
Low-set ears FREQUENT HP:0000369 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Low-set ears (HP:0000369). HP:0000369 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Documents low-set or simple ears in 9 of 24 patients (38%) in the second CHD3 cohort.
Hearing impairment OCCASIONAL HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Joint laxity was reported in 8 of 24 patients (33%). Hearing loss was uncommon, found in only 3 patients (13%)."
Documents hearing loss in 3 patients (13%) in the second CHD3 cohort.
Eye 4
Hypertelorism FREQUENT HP:0000316 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertelorism (HP:0000316). HP:0000316 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Hypertelorism (widely spaced eyes) is present in 54% of the second cohort (67% combined), a frequent feature of the recognizable facial gestalt.
Visual abnormalities FREQUENT Abnormality of vision HP:0000504 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of vision (HP:0000504). HP:0000504 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Strikingly, 18 of 24 patients in our cohort (75%) had some type of vision abnormality. A similar rate of visual impairment was reported in the initial cohort, where 70% of patients were reported as having some type of visual abnormality"
Combined cohort data shows visual abnormalities affect 72% of patients with full ophthalmologic assessment.
Strabismus FREQUENT HP:0000486 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Strabismus (HP:0000486). HP:0000486 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Strabismus was seen in 6 of the 18 patients with a reported vision abnormality in our cohort (33%, similar to the 44% reported in the initial cohort)"
Strabismus is the most common visual abnormality in the combined cohorts, affecting 39% of patients.
Deeply set eye FREQUENT HP:0000490 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Deeply set eye (HP:0000490). HP:0000490 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Documents deep-set eyes in 13 of 24 patients (54%) in the second CHD3 cohort.
Genitourinary 1
Cryptorchidism FREQUENT HP:0000028 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cryptorchidism (HP:0000028). HP:0000028 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Undescended testes and other male genitourinary anomalies, which were present in 37% of males in the initial Snijders Blok-Campeau syndrome patient cohort ... were reported in only 2 of 10 males (20%) in our cohort, with unilateral undescended testicle reported in two boys."
Documents undescended testes and other male genitourinary anomalies in 37% of males in the initial cohort and 2 of 10 males (20%) in the follow-up cohort.
Head and Neck 10
Macrocephaly FREQUENT HP:0000256 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macrocephaly (HP:0000256). HP:0000256 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32483341 SUPPORT Human clinical
"In the initial publication, macrocephaly was a reported finding in 58% of CHD3 patients. In our cohort, macrocephaly was similarly seen in 10 of 24 patients (42%)"
Combined cohort data establishes macrocephaly in 51% of fully characterized patients.
PMID:30397230 SUPPORT Human clinical
"a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language"
Macrocephaly is recognized as a defining feature of the syndrome in the original description.
Frontal bossing FREQUENT HP:0002007 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Frontal bossing (HP:0002007). HP:0002007 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Frontal bossing is a frequent craniofacial feature present in 57% of the second cohort (43% combined).
Broad nasal bridge FREQUENT Wide nasal bridge HP:0000431 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Wide nasal bridge (HP:0000431). HP:0000431 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface hypoplasia in 9 of 24 patients (38%)"
Broad nasal bridge is one of the most consistent facial features, present in 71% of the second cohort.
Thin upper lip FREQUENT Thin upper lip vermilion HP:0000219 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thin upper lip vermilion (HP:0000219). HP:0000219 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface hypoplasia in 9 of 24 patients (38%)"
Thin upper lip is a highly characteristic facial feature observed in 74% of the second cohort.
Pointed chin FREQUENT HP:0000307 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pointed chin (HP:0000307). HP:0000307 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Pointed chin is part of the recognizable facial gestalt, observed in 50% of the second cohort.
Absent teeth OCCASIONAL Hypodontia HP:0000668 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypodontia (HP:0000668). HP:0000668 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"5 patients (21% of all patients, and 33% of patients who were specifically examined for dental anomalies) were noted to have absent adult teeth"
Absent adult teeth were reported in 5 patients, placing hypodontia in the occasional frequency range for the cohort.
Narrow palpebral fissure FREQUENT HP:0045025 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Narrow palpebral fissure (HP:0045025). HP:0045025 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Documents narrow palpebral fissures in 10 of 24 patients (42%) in the second CHD3 cohort.
Sparse lateral eyebrow FREQUENT HP:0005338 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sparse lateral eyebrow (HP:0005338). HP:0005338 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%),..."
Documents laterally sparse eyebrows in 12 of 23 patients (52%) in the second CHD3 cohort.
Full cheeks FREQUENT HP:0000293 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Full cheeks (HP:0000293). HP:0000293 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"In addition to the facial features seen in the initial cohort, other common facial features were apparent in our patient cohort. These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface..."
Documents full cheeks in 13 of 24 patients (57%) in the second CHD3 cohort.
Midface retrusion FREQUENT HP:0011800 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Midface retrusion (HP:0011800). HP:0011800 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"In addition to the facial features seen in the initial cohort, other common facial features were apparent in our patient cohort. These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface..."
Documents midface hypoplasia in 9 of 24 patients (38%) in the second CHD3 cohort.
Musculoskeletal 2
Hypotonia VERY_FREQUENT HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Hypotonia was seen in 22 of 24 of our patients (92%), and autistic features were seen in 9 of 24 patients (38%)."
Cohort data establishes hypotonia in 92% of patients in the second cohort (83% combined).
Joint hypermobility FREQUENT HP:0001382 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint hypermobility (HP:0001382). HP:0001382 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Joint laxity was reported in 8 of 24 patients (33%)."
Drivas et al. report joint laxity in one-third of their cohort, supporting joint hypermobility as a frequent musculoskeletal feature.
Nervous System 8
Global developmental delay VERY_FREQUENT HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"All patients initially presented for evaluation for developmental delay, most with additional findings, and were each found to have a variant in the CHD3 gene"
Cohort data showing developmental delay in 100% of patients across both the original 2018 cohort and the second Drivas cohort (combined 59/59).
Intellectual disability VERY_FREQUENT HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32483341 SUPPORT Human clinical
"Intellectual disability was noted in 20 of 21 patients (95%, 3 individuals too young to assess)."
Cohort data shows intellectual disability in 95% of assessed patients in the second cohort (84% combined).
PMID:30397230 SUPPORT Human clinical
"We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language."
Original syndrome description identifies intellectual disability as a defining feature.
Speech delay and impaired language VERY_FREQUENT Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32483341 SUPPORT Human clinical
"Similar to the previous cohort, speech delay was seen unequivocally in all 24 of our patients."
Combined cohort data shows speech delay in 100% of fully characterized patients.
PMID:30397230 SUPPORT Human clinical
"We describe an index case with a de novo missense mutation in CHD3, identified during whole genome sequencing of a cohort of children with rare speech disorders."
Speech impairment was the original phenotype that led to discovery of CHD3 as a disease gene.
Autistic features FREQUENT Autistic behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:32483341 SUPPORT Human clinical
"Hypotonia was seen in 22 of 24 of our patients (92%), and autistic features were seen in 9 of 24 patients (38%)."
Autistic features are present in 38% of the second cohort (33% combined).
PMID:40830229 SUPPORT Human clinical
"despite profound challenges in global adaptive behavior in SNIBCPS, we reveal the social domain as showing the highest adaptive levels alongside minimal emotional/behavioral issues within the sample, suggesting relative strengths inherent to SNIBCPS"
Comprehensive neurobehavioral profiling of 38 individuals shows that the social domain is a relative strength, complementing the autistic-feature classification with the recognized hypersociability hallmark.
PMID:39988727 SUPPORT Human clinical
"Hypersociability/overfriendliness is a notable behavioral feature in patients."
Documents hypersociability/overfriendliness as a notable behavioral feature, distinct from typical autistic social withdrawal.
Speech apraxia HP:0011098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Speech apraxia (HP:0011098). HP:0011098 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31737996 SUPPORT Human clinical
"CHD3 variants are associated with inguinal hernias and apraxia of speech"
Pierson et al. NuRDopathy review identifies apraxia of speech as a relatively distinctive feature of CHD3-related SNIBCPS.
Pain insensitivity OCCASIONAL HP:0007021 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pain insensitivity (HP:0007021). HP:0007021 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40881826 SUPPORT Human clinical
"Almost a quarter of our respondents reported insensitivity in the affected individual to hard impacts or pressure."
Mixed-methods caregiver survey study of 15 SNIBCPS families documents pain insensitivity as a recognized but previously anecdotal feature of the syndrome.
Seizures OCCASIONAL HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Seizures were reported in 5 of 24 patients in our cohort (21%)."
Seizures occur in a minority of patients (21% in the second cohort, 16% combined).
Structural CNS abnormality FREQUENT Morphological central nervous system abnormality HP:0002011 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Morphological central nervous system abnormality (HP:0002011). HP:0002011 is a phenotype from the Human Phenotype Ontology.
Coarse binding: variable spectrum
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Of the 23 patients in our cohort with any brain imaging, 9 (39%) had structural central nervous system (CNS) anomalies identified. This is similar to the 57% of patients with reported CNS anomalies in the original patient cohort."
Structural CNS abnormalities, including prominent extra-axial space and delayed myelination, are seen in 49% of patients with imaging.
🧬

Genetic Associations

1
CHD3 pathogenic variants (Causative)
Gene: CHD3 hgnc:1918 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CHD3 (hgnc:1918). hgnc:1918 is a gene from the HUGO Gene Nomenclature Committee.
Autosomal dominant inheritance
Show evidence (8 references)
PMID:30397230 SUPPORT Human clinical
"we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein."
Establishes CHD3 as the causative gene with most variants being de novo missense changes in the helicase domain.
PMID:32483341 SUPPORT Human clinical
"Our analysis has shown no difference in phenotype between those patients with missense variants affecting the CHD3 helicase domain compared with patients with any other CHD3 variant type, expanding the spectrum of molecular mechanisms that are known to lead to Snijders Blok-Campeau syndrome."
Demonstrates that variants outside the helicase domain - including truncating variants, deletions, and duplications - produce the same phenotype as helicase-domain missense variants.
PMID:35346573 SUPPORT Human clinical
"We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome."
Documents inherited CHD3 variants causing Snijders Blok-Campeau syndrome with variable expressivity.
+ 5 more references
💊

Medical Actions

6
Speech and Language Therapy
Action: speech therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is speech therapy, annotated with Speech Language Therapy (NCIT:C159273). NCIT:C159273 is a clinical intervention from the NCI Thesaurus. Ontology label: Speech Language Therapy NCIT:C159273
Platform: Behavioral / lifestyle
Speech and language therapy is a cornerstone of management for the universal severe speech delay and childhood apraxia of speech features in Snijders Blok-Campeau syndrome. Augmentative and alternative communication (AAC) approaches are often necessary.
Target Phenotypes: Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology. Speech apraxia HP:0011098 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Speech apraxia (HP:0011098). HP:0011098 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30397230 SUPPORT Human clinical
"We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language."
Universal speech and language impairment in Snijders Blok-Campeau syndrome necessitates targeted speech and language therapy.
Early Developmental Intervention
Action: early intervention servicesNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is early intervention services, annotated with Early Intervention (NCIT:C159524). NCIT:C159524 is a clinical intervention from the NCI Thesaurus. Ontology label: Early Intervention NCIT:C159524
Early intervention services including occupational therapy, physical therapy, and developmental support are recommended given the universal global developmental delay seen in affected individuals.
Target Phenotypes: Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology. Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"All patients initially presented for evaluation for developmental delay, most with additional findings, and were each found to have a variant in the CHD3 gene"
Universal global developmental delay (100% across combined cohorts) warrants early multidisciplinary developmental intervention.
Antiepileptic Drug Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Standard antiepileptic medications are used to manage seizures in the approximately 16% of patients who develop epilepsy. Drug selection is guided by seizure type.
Target Phenotypes: Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Seizures were reported in 5 of 24 patients in our cohort (21%)."
Seizures occur in 16% of patients across combined cohorts (21% in the second cohort) and require standard antiepileptic pharmacotherapy.
Ophthalmologic Evaluation
Action: ophthalmologist evaluationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is ophthalmologist evaluation, annotated with Eye Examination (NCIT:C38060). NCIT:C38060 is a clinical intervention from the NCI Thesaurus. Ontology label: Eye Examination NCIT:C38060
Given the high prevalence of visual abnormalities (72%), regular ophthalmologic evaluation is recommended. Refractive error correction, strabismus management, and treatment of cortical visual impairment may be needed.
Target Phenotypes: Abnormality of vision HP:0000504 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Abnormality of vision (HP:0000504). HP:0000504 is a phenotype from the Human Phenotype Ontology. Strabismus HP:0000486 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Strabismus (HP:0000486). HP:0000486 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Strikingly, 18 of 24 patients in our cohort (75%) had some type of vision abnormality. A similar rate of visual impairment was reported in the initial cohort, where 70% of patients were reported as having some type of visual abnormality"
High prevalence of visual abnormalities (72% combined) and strabismus necessitates routine ophthalmologic evaluation and management.
Echocardiographic Evaluation
Action: echocardiographyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is echocardiography, annotated with Echocardiography Test (NCIT:C16525). NCIT:C16525 is a clinical intervention from the NCI Thesaurus. Ontology label: Echocardiography Test NCIT:C16525
Echocardiographic evaluation is recommended at diagnosis given the 14% prevalence of congenital heart defects, primarily atrial and ventricular septal defects.
Target Phenotypes: Abnormal heart morphology HP:0001627 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32483341 SUPPORT Human clinical
"Congenital heart disease (CHD) was seen in only 5 of 24 (21%) of patients, mostly accounted for by atrial septal defects (seen in 3 patients), followed by patent ductus arteriosus (in 1 patient) and ventricular septal defect (in 1 patient)."
Presence of congenital heart defects in 14% of combined cohort patients (21% in the second cohort) supports baseline echocardiographic screening.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Given the autosomal dominant inheritance pattern with variable expressivity, genetic counseling is important for families. Most cases are de novo, but inherited variants from mildly affected parents are increasingly recognized, particularly via maternal transmission.
Show evidence (1 reference)
PMID:35346573 SUPPORT Human clinical
"Our results point to a significant role of inherited variation in Snijders Blok-Campeau syndrome, a finding that is critical for correct variant interpretation and genetic counseling and warrants further investigation toward understanding the broader contributions of such variation to the..."
Explicitly highlights the importance of genetic counseling given inherited CHD3 variants with variable expressivity.
🔬

Diagnosis

1
CHD3 molecular genetic testing
Definitive diagnosis requires identification of a heterozygous pathogenic or likely pathogenic variant (missense, truncating, or copy-number variant) in CHD3 by exome/genome sequencing or multigene neurodevelopmental panels, including assessment for parental transmission given documented variable expressivity.
Genetic Testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: Heterozygous pathogenic missense variant (frequently clustering in the ATPase/helicase domain), truncating variant, or whole/partial gene deletion or duplication in CHD3.
Show evidence (2 references)
PMID:30397230 SUPPORT Human clinical
"we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein."
Establishes genotype-first molecular identification of pathogenic CHD3 variants as the definitive diagnostic modality.
PMID:32483341 SUPPORT Human clinical
"Our analysis has shown no difference in phenotype between those patients with missense variants affecting the CHD3 helicase domain compared with patients with any other CHD3 variant type, expanding the spectrum of molecular mechanisms that are known to lead to Snijders Blok-Campeau syndrome."
Demonstrates that molecular testing must evaluate both helicase-domain missense variants and truncating or copy-number variants across CHD3.
📈

Progression

1
Onset
Age: Infancy to early childhood
Manifests in infancy and early childhood with macrocephaly, intellectual disability, and severe speech and language impairment.
Show evidence (1 reference)
PMID:30397230 SUPPORT Human clinical
"We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language."
Identifies the core neurodevelopmental features of the syndrome; infancy and early childhood onset is established across the clinical cohorts.
📊

Prevalence

1
Published clinical cohorts
Cases/families reported in the literature Ultra-rare
Ultra-rare neurodevelopmental syndrome with fewer than 150 published individuals across initial de novo cohorts (35 in the 2018 discovery cohort; 24 additional in Drivas et al. 2020) and 21 inherited-variant families (van der Spek et al. 2022).
Show evidence (2 references)
PMID:32483341 SUPPORT Human clinical
"Here we have presented the second large cohort of Snijders Blok-Campeau syndrome patients with variants in the CHD3 gene, bringing the total number of known patients to 59."
Summarizes the combined 59 patients across the first two published cohorts of Snijders Blok-Campeau syndrome.
PMID:35346573 SUPPORT Human clinical
"We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome."
Documents 21 additional families with inherited heterozygous CHD3 variants.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Snijders Blok-Campeau Syndrome:

Sifrim-Hitz-Weiss syndrome MONDO:0014946
Overlapping Features CHD4-related NuRDopathy (Sifrim-Hitz-Weiss syndrome) shares macrocephaly, intellectual disability, hypotonia, and overlapping facial dysmorphism with Snijders Blok-Campeau syndrome, but is distinguished by higher rates of congenital heart defects, skeletal anomalies, and deafness/hearing loss, whereas CHD3 variants more characteristically feature childhood apraxia of speech and inguinal hernias.
Distinguishing Features
  • CHD4 pathogenic variants rather than CHD3 variants on molecular genetic testing
  • Higher prevalence of skeletal anomalies, hearing loss, and cardiac defects in CHD4-related disorder versus speech apraxia and inguinal hernia in CHD3-related disorder
Show evidence (1 reference)
PMID:31737996 SUPPORT Human clinical
"In addition to macrocephaly and intellectual disability, CHD3 variants are associated with inguinal hernias and apraxia of speech; whereas CHD4 variants are associated with skeletal anomalies, deafness, and cardiac defects. GATAD2B-associated neurodevelopmental disorder (GAND) has phenotypic..."
Directly compares the clinical spectrum and distinguishing features of CHD3-related Snijders Blok-Campeau syndrome and CHD4-related Sifrim-Hitz-Weiss syndrome.
GATAD2B-associated neurodevelopmental disorder Not Yet Curated MONDO:0014034
Overlapping Features GATAD2B-associated neurodevelopmental disorder (GAND) is a fellow NuRDopathy that overlaps clinically with Snijders Blok-Campeau syndrome through macrocephaly, intellectual disability, hypotonia, severe speech impairment, and facial dysmorphism, requiring molecular genetic testing of GATAD2B versus CHD3 for definitive differentiation.
Distinguishing Features
  • Heterozygous pathogenic variants in GATAD2B rather than CHD3 on molecular genetic testing
  • Lacks the characteristic clustering of inguinal hernias and childhood apraxia of speech associated with CHD3 variants
Show evidence (1 reference)
PMID:31737996 SUPPORT Human clinical
"In addition to macrocephaly and intellectual disability, CHD3 variants are associated with inguinal hernias and apraxia of speech; whereas CHD4 variants are associated with skeletal anomalies, deafness, and cardiac defects. GATAD2B-associated neurodevelopmental disorder (GAND) has phenotypic..."
Identifies GATAD2B-associated neurodevelopmental disorder (GAND) as an overlapping NuRDopathy differential diagnosis for CHD3-related Snijders Blok-Campeau syndrome.
🔬

Clinical Trials

1
NCT06860672 PHASE_I RECRUITING
First-in-human early-phase trial of a single intrathecal injection of a dual vector AAV-delivered base editor designed to correct the recurrent CHD3 c.3073C>T (p.R1025W) variant in pediatric patients with Snijders Blok-Campeau syndrome. Represents one of the first in-vivo base-editing approaches for any chromatinopathy.
Target Phenotypes: Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology. Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06860672 SUPPORT Human clinical
"To evaluate the safety, tolerability and preliminary efficacy study of a single intrathecal injection of the dual vector AAV-CHD3-R1025W base editor for the treatment of developmental disorders caused by the R1025W mutation in the CHD3 gene"
Documents the active first-in-human trial of allele-specific AAV base editing targeting the recurrent CHD3 R1025W variant, a landmark therapeutic development for SNIBCPS.
{ }

Source YAML

click to show 
name: Snijders Blok-Campeau Syndrome
creation_date: '2026-04-16T00:00:00Z'
category: Mendelian
synonyms:
- SNIBCPS
- CHD3-related neurodevelopmental disorder
- Intellectual developmental disorder with macrocephaly, speech delay, and dysmorphic facies
- CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome
description: Snijders Blok-Campeau syndrome (SNIBCPS; OMIM 618205) is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in CHD3 (chromodomain helicase DNA-binding protein 3) at chromosome 17p13.1. CHD3 encodes an ATP-dependent chromatin remodeler that is a catalytic subunit of the NuRD (Nucleosome Remodeling and Deacetylase) complex, which couples chromatin remodeling with histone deacetylation to regulate gene expression during brain development. The syndrome is characterized by global developmental delay, intellectual disability, severe speech and language impairment (including childhood apraxia of speech), macrocephaly, hypotonia, and a recognizable facial gestalt featuring frontal bossing, hypertelorism, broad nasal bridge, prominent forehead, deep-set eyes, and pointed chin. Inguinal hernias and a distinctive hypersociability/overfriendliness behavior — recapitulated in zebrafish chd3 knockouts — are additional features. SNIBCPS is grouped with CHD4-related Sifrim-Hitz-Weiss syndrome and GATAD2B-related GAND in the emerging "NuRDopathy" class of macrocephaly-associated neurodevelopmental disorders. Most pathogenic variants are de novo
  missense changes clustering in the catalytic ATPase/helicase domain (with a striking enrichment of arginine substitutions), but truncating variants and copy-number changes outside this domain produce an indistinguishable dominant phenotype, while rare biallelic variants cause a more severe neurocognitive syndrome. Variable expressivity has been documented, with some inherited variants present in mildly or unaffected parents. A first-in-human AAV base-editing gene therapy trial for the recurrent R1025W variant has entered Phase I (NCT06860672).
disease_term:
  preferred_term: Snijders Blok-Campeau syndrome
  term:
    id: MONDO:0032600
    label: Snijders Blok-Campeau syndrome
parents:
- Neurodevelopmental disorder
- Chromatinopathy
- NuRDopathy
- Intellectual disability syndrome
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:30397230
      reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.
      explanation: Establishes Snijders Blok-Campeau syndrome as a monogenic hereditary neurodevelopmental disorder caused by pathogenic CHD3 variants.
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:30397230
      reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.
      explanation: Intellectual disability, macrocephaly, and impaired speech and language reflect primary central nervous system involvement.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: Autosomal dominant inheritance, most commonly arising de novo via heterozygous missense or truncating variants in CHD3, though inherited heterozygous variants with variable expressivity (predominantly maternally transmitted) are also documented.
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein.
    explanation: Establishes heterozygous de novo CHD3 variants as the primary cause of autosomal dominant Snijders Blok-Campeau syndrome.
  - reference: PMID:35346573
    reference_title: Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome.
    explanation: Demonstrates autosomal dominant transmission with variable expressivity in multi-generational families.
prevalence:
- population: Published clinical cohorts
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: Ultra-rare neurodevelopmental syndrome with fewer than 150 published individuals across initial de novo cohorts (35 in the 2018 discovery cohort; 24 additional in Drivas et al. 2020) and 21 inherited-variant families (van der Spek et al. 2022).
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we have presented the second large cohort of Snijders Blok-Campeau syndrome patients with variants in the CHD3 gene, bringing the total number of known patients to 59.
    explanation: Summarizes the combined 59 patients across the first two published cohorts of Snijders Blok-Campeau syndrome.
  - reference: PMID:35346573
    reference_title: Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome.
    explanation: Documents 21 additional families with inherited heterozygous CHD3 variants.
progression:
- phase: Onset
  age_range: Infancy to early childhood
  notes: Manifests in infancy and early childhood with macrocephaly, intellectual disability, and severe speech and language impairment.
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.
    explanation: Identifies the core neurodevelopmental features of the syndrome; infancy and early childhood onset is established across the clinical cohorts.
pathophysiology:
- name: CHD3-dependent NuRD chromatin remodeling defects
  description: CHD3 is an ATP-dependent chromatin remodeling enzyme that uses energy from ATP hydrolysis to slide and reposition nucleosomes along DNA. It is one of three mutually exclusive catalytic subunits (CHD3, CHD4, CHD5) of the NuRD complex, which couples chromatin remodeling with histone deacetylation to regulate gene expression. Pathogenic missense variants cluster within the central ATPase/helicase domain and disrupt critical binding and interaction motifs. Functional assays show that a subset of variants directly impair ATPase activity, while nearly all yield alterations in chromatin remodeling. Both gain- and loss-of-function effects, as well as haploinsufficiency from truncating and whole-gene copy-number changes, can produce the same clinical phenotype.
  gene:
    preferred_term: CHD3
    term:
      id: hgnc:1918
      label: CHD3
    modifier: ABNORMAL
  molecular_functions:
  - preferred_term: ATP-dependent chromatin remodeler activity
    term:
      id: GO:0140658
      label: ATP-dependent chromatin remodeler activity
    modifier: ABNORMAL
  - preferred_term: chromatin binding
    term:
      id: GO:0003682
      label: chromatin binding
    modifier: ABNORMAL
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DECREASED
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Disrupted NuRD-dependent cortical layer specification
    causal_link_type: DIRECT
  - target: Disrupted BMP/Wnt signaling in cranial neural crest cell specification
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs.
    explanation: Establishes the structural and functional impact of CHD3 missense mutations on the ATPase/helicase domain.
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling.
    explanation: Demonstrates the molecular consequences of CHD3 mutations on chromatin remodeling activity.
- name: Disrupted NuRD-dependent cortical layer specification
  description: 'The Mi-2/NuRD (Nucleosome Remodeling and Deacetylase) complex couples ATP-dependent chromatin remodeling (via mutually exclusive CHD3, CHD4, or CHD5 subunits) with histone deacetylation (via HDAC1/2). During mouse cortical development a sequential subunit switch assigns non-redundant developmental roles: CHD4 drives early progenitor proliferation, CHD5 facilitates radial neuronal migration, and CHD3 is specifically required for proper cortical layer specification. Inhibition of any one CHD cannot be rescued by overexpression of another, indicating CHD3''s role in the NuRD complex is irreplaceable. Loss of CHD3 catalytic function in NuRD therefore disturbs late transcriptional programs governing layer identity and post-mitotic neuronal differentiation, providing a mechanistic substrate for the intellectual disability, speech/language impairment, and structural cortical findings observed in SNIBCPS. Together with CHD4 (Sifrim-Hitz-Weiss) and GATAD2B (GAND) disorders, SNIBCPS belongs to a "NuRDopathy" class of macrocephaly-associated neurodevelopmental disorders sharing intellectual disability, hypotonia and overlapping facial features.'
  gene:
    preferred_term: CHD3
    term:
      id: hgnc:1918
      label: CHD3
    modifier: ABNORMAL
  cell_types:
  - preferred_term: neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  - preferred_term: cortical projection neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DYSREGULATED
  - preferred_term: cerebral cortex development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Chromatin remodeling is of crucial importance during brain development. Pathogenic alterations of several chromatin remodeling ATPases have been implicated in neurodevelopmental disorders.
    explanation: Frames the broader rationale that disruption of chromatin remodeling ATPases like CHD3 results in neurodevelopmental disease.
  - reference: PMID:27806305
    reference_title: A Functional Switch of NuRD Chromatin Remodeling Complex Subunits Regulates Mouse Cortical Development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Whereas CHD4 promotes the early proliferation of progenitors, CHD5 facilitates neuronal migration and CHD3 ensures proper layer specification.
    explanation: In vivo mouse cortical development experiments establish that CHD3 has a specific, non-redundant role in cortical layer specification that cannot be substituted by CHD4 or CHD5, providing the developmental substrate for SNIBCPS cortical phenotypes.
  - reference: PMID:27806305
    reference_title: A Functional Switch of NuRD Chromatin Remodeling Complex Subunits Regulates Mouse Cortical Development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Inhibition of each CHD leads to defects of neuronal differentiation and migration, which cannot be rescued by expressing heterologous CHDs.
    explanation: Demonstrates the non-interchangeable function of CHD3 within NuRD and explains why CHD3 haploinsufficiency cannot be functionally compensated by paralogs.
  - reference: PMID:31737996
    reference_title: The NuRD complex and macrocephaly associated neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The nucleosome remodeling and deacetylase (NuRD) complex is a major regulator of gene expression involved in pluripotency, lineage commitment, and corticogenesis. This important complex is composed of seven different proteins, with mutations in CHD3, CHD4, and GATAD2B being associated with neurodevelopmental disorders presenting with macrocephaly and intellectual disability
    explanation: Establishes the NuRDopathy disease class linking CHD3, CHD4 and GATAD2B disorders by their shared NuRD complex biology and overlapping macrocephaly/ID phenotype.
  downstream:
  - target: Global developmental delay
    causal_link_type: DIRECT
  - target: Intellectual disability
    causal_link_type: DIRECT
  - target: Speech delay and impaired language
    causal_link_type: DIRECT
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Macrocephaly
    causal_link_type: DIRECT
  - target: Autistic features
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Speech apraxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Pain insensitivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Structural CNS abnormality
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Disrupted BMP/Wnt signaling in cranial neural crest cell specification
  description: During cranial neural crest cell (CNCC) specification, CHD3 is upregulated in early CNCCs and is required to enhance the BMP signalling response by opening chromatin at BMP-responsive cis-regulatory elements and by increasing expression of BMP-responsive transcription factors, including DLX paralogs. CHD3 loss in iPSC-derived CNCCs represses BMP target genes and reduces chromatin accessibility at these elements, producing an imbalance between BMP and Wnt signalling that diverts cells away from a CNCC fate toward aberrant early-mesoderm identity. Partial rescue by titrating Wnt levels demonstrates a causal role for the BMP/Wnt imbalance and points to a candidate therapeutic axis. This mechanism provides a direct molecular explanation for the recognizable craniofacial gestalt of SNIBCPS (frontal bossing, hypertelorism, broad nasal bridge, midface findings) by linking CHD3 chromatin remodeling activity to neural crest-derived craniofacial development.
  gene:
    preferred_term: CHD3
    term:
      id: hgnc:1918
      label: CHD3
    modifier: DECREASED
  cell_types:
  - preferred_term: cranial neural crest cell
    term:
      id: CL:0011012
      label: neural crest cell
  biological_processes:
  - preferred_term: BMP signaling pathway
    term:
      id: GO:0030509
      label: BMP signaling pathway
    modifier: DECREASED
  - preferred_term: neural crest cell differentiation
    term:
      id: GO:0014033
      label: neural crest cell differentiation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:40835974
    reference_title: The NuRD component CHD3 promotes BMP signalling during cranial neural crest cell specification.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In control lines, CHD3 is upregulated in early stages of CNCC specification, where it enhances the BMP signalling response by opening chromatin at BMP-responsive cis-regulatory elements and by increasing expression of BMP-responsive transcription factors, including DLX paralogs.
    explanation: Establishes CHD3's positive regulatory role in BMP signaling during normal cranial neural crest cell specification using human iPSC-derived models.
  - reference: PMID:40835974
    reference_title: The NuRD component CHD3 promotes BMP signalling during cranial neural crest cell specification.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: CHD3 loss leads to repression of BMP target genes and loss of chromatin accessibility at cis-regulatory elements usually bound by BMP-responsive factors, causing an imbalance between BMP and Wnt signalling. Consequently, the CNCC specification fails, replaced by aberrant early-mesoderm identity, which can be partially rescued by titrating Wnt levels.
    explanation: Demonstrates that CHD3 loss disrupts BMP/Wnt balance in CNCCs and identifies Wnt modulation as a potential therapeutic strategy for the craniofacial features of SNIBCPS.
  - reference: PMID:40835974
    reference_title: The NuRD component CHD3 promotes BMP signalling during cranial neural crest cell specification.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Our findings highlight a novel role for CHD3 as a pivotal regulator of BMP signalling, essential for proper neural crest specification and craniofacial development.
    explanation: Directly links CHD3 dysfunction to the craniofacial phenotype of SNIBCPS through its role in cranial neural crest specification.
  downstream:
  - target: Joint hypermobility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Frontal bossing
    causal_link_type: DIRECT
  - target: Hypertelorism
    causal_link_type: DIRECT
  - target: Broad nasal bridge
    causal_link_type: DIRECT
  - target: Deeply set eye
    causal_link_type: DIRECT
  - target: Narrow palpebral fissure
    causal_link_type: DIRECT
  - target: Sparse lateral eyebrow
    causal_link_type: DIRECT
  - target: Low-set ears
    causal_link_type: DIRECT
  - target: Full cheeks
    causal_link_type: DIRECT
  - target: Midface retrusion
    causal_link_type: DIRECT
  - target: Thin upper lip
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Pointed chin
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Absent teeth
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Visual abnormalities
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Strabismus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hearing impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Inguinal hernia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cryptorchidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Congenital heart defects
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- category: Neurological
  name: Global developmental delay
  frequency: VERY_FREQUENT
  description: Global developmental delay is universal in Snijders Blok-Campeau syndrome, affecting motor, cognitive, and language milestones. Reported in 100% (24/24) of the second cohort and 100% (35/35) of the original cohort.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients initially presented for evaluation for developmental delay, most with additional findings, and were each found to have a variant in the CHD3 gene
    explanation: Cohort data showing developmental delay in 100% of patients across both the original 2018 cohort and the second Drivas cohort (combined 59/59).
- category: Neurological
  name: Intellectual disability
  frequency: VERY_FREQUENT
  description: Intellectual disability is present in approximately 84% of patients (47/56 combined cohorts), spanning the spectrum from mild (34%) to moderate (36%) to severe (23%).
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Intellectual disability was noted in 20 of 21 patients (95%, 3 individuals too young to assess).
    explanation: Cohort data shows intellectual disability in 95% of assessed patients in the second cohort (84% combined).
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.
    explanation: Original syndrome description identifies intellectual disability as a defining feature.
- category: Neurological
  name: Speech delay and impaired language
  frequency: VERY_FREQUENT
  description: Speech and language delay is universal, occurring in 100% (57/57) of combined cohorts. The phenotype includes severe expressive speech delay and features of childhood apraxia of speech. CHD3 was originally identified during whole genome sequencing of a cohort of children with rare speech disorders.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Similar to the previous cohort, speech delay was seen unequivocally in all 24 of our patients.
    explanation: Combined cohort data shows speech delay in 100% of fully characterized patients.
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We describe an index case with a de novo missense mutation in CHD3, identified during whole genome sequencing of a cohort of children with rare speech disorders.
    explanation: Speech impairment was the original phenotype that led to discovery of CHD3 as a disease gene.
- category: Neurological
  name: Hypotonia
  frequency: VERY_FREQUENT
  description: Muscular hypotonia is present in approximately 83% of patients (43/52 combined cohorts) and is typically apparent from infancy.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hypotonia was seen in 22 of 24 of our patients (92%), and autistic features were seen in 9 of 24 patients (38%).
    explanation: Cohort data establishes hypotonia in 92% of patients in the second cohort (83% combined).
- category: Musculoskeletal
  name: Joint hypermobility
  frequency: FREQUENT
  description: Joint laxity or hypermobility is reported in approximately 33% of patients (8/24) in the Drivas cohort.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Joint laxity was reported in 8 of 24 patients (33%).
    explanation: Drivas et al. report joint laxity in one-third of their cohort, supporting joint hypermobility as a frequent musculoskeletal feature.
- category: Craniofacial
  name: Macrocephaly
  frequency: FREQUENT
  description: Macrocephaly is a hallmark feature, present in approximately 51% of patients (29/57 combined cohorts). Microcephaly is rare (5%).
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the initial publication, macrocephaly was a reported finding in 58% of CHD3 patients. In our cohort, macrocephaly was similarly seen in 10 of 24 patients (42%)
    explanation: Combined cohort data establishes macrocephaly in 51% of fully characterized patients.
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language
    explanation: Macrocephaly is recognized as a defining feature of the syndrome in the original description.
- category: Craniofacial
  name: Frontal bossing
  frequency: FREQUENT
  description: Prominent or bulging forehead (frontal bossing) is present in approximately 43% of patients (24/56 combined cohorts).
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%)
    explanation: Frontal bossing is a frequent craniofacial feature present in 57% of the second cohort (43% combined).
- category: Craniofacial
  name: Hypertelorism
  frequency: FREQUENT
  description: Widely spaced eyes (ocular hypertelorism) is present in approximately 67% of patients (37/55 combined cohorts).
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%)
    explanation: Hypertelorism (widely spaced eyes) is present in 54% of the second cohort (67% combined), a frequent feature of the recognizable facial gestalt.
- category: Craniofacial
  name: Broad nasal bridge
  frequency: FREQUENT
  description: A broad nasal bridge is a recognizable facial feature, present in 71% of patients (17/24) in the second cohort.
  phenotype_term:
    preferred_term: Wide nasal bridge
    term:
      id: HP:0000431
      label: Wide nasal bridge
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface hypoplasia in 9 of 24 patients (38%)
    explanation: Broad nasal bridge is one of the most consistent facial features, present in 71% of the second cohort.
- category: Craniofacial
  name: Thin upper lip
  frequency: FREQUENT
  description: A thin upper lip vermilion is one of the most distinctive facial features, present in 74% of patients (17/23) in the second cohort.
  phenotype_term:
    preferred_term: Thin upper lip vermilion
    term:
      id: HP:0000219
      label: Thin upper lip vermilion
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface hypoplasia in 9 of 24 patients (38%)
    explanation: Thin upper lip is a highly characteristic facial feature observed in 74% of the second cohort.
- category: Craniofacial
  name: Pointed chin
  frequency: FREQUENT
  description: A pointed chin is a characteristic facial feature, present in 50% of patients (12/24) in the second cohort and becoming more prominent with age.
  phenotype_term:
    preferred_term: Pointed chin
    term:
      id: HP:0000307
      label: Pointed chin
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%)
    explanation: Pointed chin is part of the recognizable facial gestalt, observed in 50% of the second cohort.
- category: Craniofacial
  name: Absent teeth
  frequency: OCCASIONAL
  description: Hypodontia with absent adult teeth was reported in 5 patients, corresponding to 21% of all patients and 33% of those specifically examined for dental anomalies.
  phenotype_term:
    preferred_term: Hypodontia
    term:
      id: HP:0000668
      label: Hypodontia
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 5 patients (21% of all patients, and 33% of patients who were specifically examined for dental anomalies) were noted to have absent adult teeth
    explanation: Absent adult teeth were reported in 5 patients, placing hypodontia in the occasional frequency range for the cohort.
- category: Ophthalmologic
  name: Visual abnormalities
  frequency: FREQUENT
  description: Visual abnormalities are highly prevalent (72%, 41/57 combined cohorts), most commonly strabismus (39%), hyperopia (34%), cortical visual impairment (17%), astigmatism (10%), and myopia (10%).
  phenotype_term:
    preferred_term: Abnormality of vision
    term:
      id: HP:0000504
      label: Abnormality of vision
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Strikingly, 18 of 24 patients in our cohort (75%) had some type of vision abnormality. A similar rate of visual impairment was reported in the initial cohort, where 70% of patients were reported as having some type of visual abnormality
    explanation: Combined cohort data shows visual abnormalities affect 72% of patients with full ophthalmologic assessment.
- category: Ophthalmologic
  name: Strabismus
  frequency: FREQUENT
  description: Strabismus is the most common ocular finding, present in approximately 39% of patients (16/41 combined cohorts).
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Strabismus was seen in 6 of the 18 patients with a reported vision abnormality in our cohort (33%, similar to the 44% reported in the initial cohort)
    explanation: Strabismus is the most common visual abnormality in the combined cohorts, affecting 39% of patients.
- category: Behavioral
  name: Autistic features
  frequency: FREQUENT
  description: Autistic features are reported in approximately 33% of patients (18/55 combined cohorts). Despite challenges in adaptive behavior, the social domain shows the highest adaptive levels among neurobehavioral domains in SNIBCPS, consistent with the hypersociability/overfriendliness that is recognized as a notable behavioral feature of this syndrome.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hypotonia was seen in 22 of 24 of our patients (92%), and autistic features were seen in 9 of 24 patients (38%).
    explanation: Autistic features are present in 38% of the second cohort (33% combined).
  - reference: PMID:40830229
    reference_title: Neurobehavioral profile of individuals with pathogenic variants in CHD3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: despite profound challenges in global adaptive behavior in SNIBCPS, we reveal the social domain as showing the highest adaptive levels alongside minimal emotional/behavioral issues within the sample, suggesting relative strengths inherent to SNIBCPS
    explanation: Comprehensive neurobehavioral profiling of 38 individuals shows that the social domain is a relative strength, complementing the autistic-feature classification with the recognized hypersociability hallmark.
  - reference: PMID:39988727
    reference_title: Two distinct phenotypes in Snijders Blok-Campeau syndrome and characterization of the behavioral phenotype in a zebrafish model.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hypersociability/overfriendliness is a notable behavioral feature in patients.
    explanation: Documents hypersociability/overfriendliness as a notable behavioral feature, distinct from typical autistic social withdrawal.
- category: Neurological
  name: Speech apraxia
  description: Childhood apraxia of speech is a relatively distinctive feature of SNIBCPS. It is the motor speech component contributing to the universally severe speech delay phenotype and was the original speech disorder presentation that led to identification of CHD3 as a disease gene.
  phenotype_term:
    preferred_term: Speech apraxia
    term:
      id: HP:0011098
      label: Speech apraxia
  evidence:
  - reference: PMID:31737996
    reference_title: The NuRD complex and macrocephaly associated neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CHD3 variants are associated with inguinal hernias and apraxia of speech
    explanation: Pierson et al. NuRDopathy review identifies apraxia of speech as a relatively distinctive feature of CHD3-related SNIBCPS.
- category: Other
  name: Inguinal hernia
  frequency: OCCASIONAL
  description: Inguinal hernia is a relatively distinctive extracerebral feature of SNIBCPS within the NuRDopathy spectrum. Pooled umbilical, inguinal, and hiatal hernias were reported in 18% of the initial cohort and 4% (1/24) of the second cohort (~12% combined).
  phenotype_term:
    preferred_term: Inguinal hernia
    term:
      id: HP:0000023
      label: Inguinal hernia
  evidence:
  - reference: PMID:31737996
    reference_title: The NuRD complex and macrocephaly associated neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CHD3 variants are associated with inguinal hernias and apraxia of speech
    explanation: Pierson et al. NuRDopathy review identifies inguinal hernia as a distinguishing feature of CHD3-related SNIBCPS that helps separate it from CHD4 and GATAD2B disorders.
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Umbilical, inguinal, and hiatal hernias, which were frequently reported in the initial patient cohort (18% of cases) ... were noted in only one of the patients presented here (4%).
    explanation: Documents pooled hernia frequency across the first (18%) and second (4%) cohorts (~12% combined), supporting OCCASIONAL frequency.
- category: Neurological
  name: Pain insensitivity
  frequency: OCCASIONAL
  description: A subset of individuals with SNIBCPS show decreased pain perception or response to painful stimuli, including insensitivity to hard impacts or pressure reported in approximately a quarter of caregivers surveyed. This has important implications for medical evaluation, safety surveillance, and pain assessment using individualized observational scales.
  phenotype_term:
    preferred_term: Pain insensitivity
    term:
      id: HP:0007021
      label: Pain insensitivity
  evidence:
  - reference: PMID:40881826
    reference_title: Pain experience and perception in individuals with Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Almost a quarter of our respondents reported insensitivity in the affected individual to hard impacts or pressure.
    explanation: Mixed-methods caregiver survey study of 15 SNIBCPS families documents pain insensitivity as a recognized but previously anecdotal feature of the syndrome.
- category: Neurological
  name: Seizures
  frequency: OCCASIONAL
  description: Seizures occur in approximately 16% of patients (9/55 combined cohorts).
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures were reported in 5 of 24 patients in our cohort (21%).
    explanation: Seizures occur in a minority of patients (21% in the second cohort, 16% combined).
- category: Neurological
  name: Structural CNS abnormality
  frequency: FREQUENT
  description: Structural CNS abnormalities are present in approximately 49% of patients (25/51 combined cohorts), most commonly prominent extra-axial space (54% of those imaged) and delayed myelination.
  phenotype_term:
    preferred_term: Morphological central nervous system abnormality
    term:
      id: HP:0002011
      label: Morphological central nervous system abnormality
    coarse_binding_basis: VARIABLE_SPECTRUM
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the 23 patients in our cohort with any brain imaging, 9 (39%) had structural central nervous system (CNS) anomalies identified. This is similar to the 57% of patients with reported CNS anomalies in the original patient cohort.
    explanation: Structural CNS abnormalities, including prominent extra-axial space and delayed myelination, are seen in 49% of patients with imaging.
- category: Cardiovascular
  name: Congenital heart defects
  frequency: OCCASIONAL
  description: Congenital heart disease occurs in approximately 14% of patients (8/59 combined cohorts), most commonly atrial septal defect (50%), ventricular septal defect (25%), and patent ductus arteriosus.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Congenital heart disease (CHD) was seen in only 5 of 24 (21%) of patients, mostly accounted for by atrial septal defects (seen in 3 patients), followed by patent ductus arteriosus (in 1 patient) and ventricular septal defect (in 1 patient).
    explanation: Congenital heart defects (CHD) occur in 14% of combined cohort patients, most commonly atrial septal defects.
- category: Head and Neck
  name: Deeply set eye
  frequency: FREQUENT
  description: Deeply set eyes are part of the characteristic periocular facial gestalt in Snijders Blok-Campeau syndrome, reported in 13 of 24 patients (54%) in the second cohort.
  phenotype_term:
    preferred_term: Deeply set eye
    term:
      id: HP:0000490
      label: Deeply set eye
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%) [12].
    explanation: Documents deep-set eyes in 13 of 24 patients (54%) in the second CHD3 cohort.
- category: Head and Neck
  name: Narrow palpebral fissure
  frequency: FREQUENT
  description: Narrow palpebral fissures are a frequent periocular craniofacial feature of Snijders Blok-Campeau syndrome, reported in 10 of 24 patients (42%) in the second cohort.
  phenotype_term:
    preferred_term: Narrow palpebral fissure
    term:
      id: HP:0045025
      label: Narrow palpebral fissure
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%) [12].
    explanation: Documents narrow palpebral fissures in 10 of 24 patients (42%) in the second CHD3 cohort.
- category: Head and Neck
  name: Sparse lateral eyebrow
  frequency: FREQUENT
  description: Laterally sparse eyebrows are a recurrent periorbital dysmorphic feature of Snijders Blok-Campeau syndrome, reported in 12 of 23 patients (52%) in the second cohort.
  phenotype_term:
    preferred_term: Sparse lateral eyebrow
    term:
      id: HP:0005338
      label: Sparse lateral eyebrow
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%) [12].
    explanation: Documents laterally sparse eyebrows in 12 of 23 patients (52%) in the second CHD3 cohort.
- category: Head and Neck
  name: Low-set ears
  frequency: FREQUENT
  description: Low-set or simple ears are reported in 9 of 24 patients (38%) in the second Snijders Blok-Campeau syndrome cohort.
  phenotype_term:
    preferred_term: Low-set ears
    term:
      id: HP:0000369
      label: Low-set ears
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort confirms these observations, finding widely spaced eyes in 13 of 24 patients (54%), prominent/bossed forehead in 13 of 23 patients (57%), deep-set eyes in 13 of 24 patients (54%), narrow palpebral fissures in 10 of 24 patients (42%), laterally sparse eyebrows in 12/23 patients (52%), low set or simple ears in 9 of 24 patients (38%), and a pointed chin in 12 of 24 patients (50%) [12].
    explanation: Documents low-set or simple ears in 9 of 24 patients (38%) in the second CHD3 cohort.
- category: Head and Neck
  name: Full cheeks
  frequency: FREQUENT
  description: Full cheeks are part of the characteristic facial gestalt in Snijders Blok-Campeau syndrome, reported in 13 of 24 patients (57%) in the second cohort.
  phenotype_term:
    preferred_term: Full cheeks
    term:
      id: HP:0000293
      label: Full cheeks
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition to the facial features seen in the initial cohort, other common facial features were apparent in our patient cohort. These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface hypoplasia in 9 of 24 patients (38%), with a general, but difficult to quantify, square and boxy appearance of the face in most patients, especially at younger ages.
    explanation: Documents full cheeks in 13 of 24 patients (57%) in the second CHD3 cohort.
- category: Head and Neck
  name: Midface retrusion
  frequency: FREQUENT
  description: Midface retrusion (midface hypoplasia) is part of the neural crest-derived craniofacial phenotype of Snijders Blok-Campeau syndrome, reported in 9 of 24 patients (38%) in the second cohort.
  phenotype_term:
    preferred_term: Midface retrusion
    term:
      id: HP:0011800
      label: Midface retrusion
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition to the facial features seen in the initial cohort, other common facial features were apparent in our patient cohort. These include a thin upper lip in 17 of 23 patients (74%), broad nasal bridge in 17 of 24 patients (71%), full cheeks in 13 of 24 patients (57%), and midface hypoplasia in 9 of 24 patients (38%), with a general, but difficult to quantify, square and boxy appearance of the face in most patients, especially at younger ages.
    explanation: Documents midface hypoplasia in 9 of 24 patients (38%) in the second CHD3 cohort.
- category: Genitourinary
  name: Cryptorchidism
  frequency: FREQUENT
  description: Undescended testes and other male genitourinary anomalies were reported in 37% of males in the initial cohort and in 2 of 10 males (20%, unilateral undescended testicle) in the second cohort.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Undescended testes and other male genitourinary anomalies, which were present in 37% of males in the initial Snijders Blok-Campeau syndrome patient cohort ... were reported in only 2 of 10 males (20%) in our cohort, with unilateral undescended testicle reported in two boys.
    explanation: Documents undescended testes and other male genitourinary anomalies in 37% of males in the initial cohort and 2 of 10 males (20%) in the follow-up cohort.
- category: Ear
  name: Hearing impairment
  frequency: OCCASIONAL
  description: Hearing loss is an occasional feature of Snijders Blok-Campeau syndrome, reported in 3 of 23 patients (13%) in the second cohort.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Joint laxity was reported in 8 of 24 patients (33%). Hearing loss was uncommon, found in only 3 patients (13%).
    explanation: Documents hearing loss in 3 patients (13%) in the second CHD3 cohort.
genetic:
- name: CHD3 pathogenic variants
  association: Causative
  gene_term:
    preferred_term: CHD3
    term:
      id: hgnc:1918
      label: CHD3
  features: Heterozygous pathogenic variants in CHD3 are causative. Most variants are de novo, with the majority being missense substitutions clustering in the central ATPase/helicase domain. Other mechanisms include truncating variants, in-frame deletions, whole-gene deletions, and duplications outside the helicase domain - all producing indistinguishable clinical phenotypes. A minority of cases have inherited variants from mildly or unaffected parents, demonstrating variable expressivity. Inherited variants are most often maternally transmitted.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    evidence:
    - reference: PMID:30397230
      reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein.
      explanation: Heterozygous de novo CHD3 variants cause the syndrome, consistent with an autosomal dominant inheritance pattern.
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein.
    explanation: Establishes CHD3 as the causative gene with most variants being de novo missense changes in the helicase domain.
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our analysis has shown no difference in phenotype between those patients with missense variants affecting the CHD3 helicase domain compared with patients with any other CHD3 variant type, expanding the spectrum of molecular mechanisms that are known to lead to Snijders Blok-Campeau syndrome.
    explanation: Demonstrates that variants outside the helicase domain - including truncating variants, deletions, and duplications - produce the same phenotype as helicase-domain missense variants.
  - reference: PMID:35346573
    reference_title: Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome.
    explanation: Documents inherited CHD3 variants causing Snijders Blok-Campeau syndrome with variable expressivity.
  - reference: PMID:35346573
    reference_title: Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Notably, most inherited CHD3 variants were maternally transmitted.
    explanation: Documents the predominance of maternal transmission for inherited CHD3 variants in this syndrome.
  - reference: PMID:38116750
    reference_title: A severe neurocognitive phenotype caused by biallelic CHD3 variants in two siblings.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report a severe neurocognitive phenotype caused by biallelic CHD3 variants in two siblings, each inherited from a mildly affected parent.
    explanation: Documents that rare biallelic CHD3 variants cause a more severe neurocognitive phenotype than the classic heterozygous SNIBCPS, consistent with dosage sensitivity of CHD3.
  - reference: PMID:38116750
    reference_title: A severe neurocognitive phenotype caused by biallelic CHD3 variants in two siblings.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Biallelic CHD3 variants cause a severe neurodevelopmental syndrome that is distinguishable from SBCS.
    explanation: Establishes biallelic CHD3 disease as a distinct, more severe entity than classic monoallelic SNIBCPS.
  - reference: PMID:39542866
    reference_title: Insights From a Novel Splicing Variant and Recurrent Arginine Variants in the CHD3 Gene Causing Snijders Blok-Campeau Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Given the high prevalence of arginine residue pathogenic variants in the CHD3 protein and its notable propensity for binding and storing ATP molecules
    explanation: Highlights the disproportionate enrichment of arginine residue pathogenic variants in CHD3, consistent with the importance of these residues for ATP binding within the helicase domain.
  - reference: CGGV:assertion_0e94c7c1-9c13-4189-8a9f-e9808916526f-2022-03-02T170000.000Z
    reference_title: CHD3 / Snijders Blok-Campeau syndrome (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: CHD3 | HGNC:1918 | Snijders Blok-Campeau syndrome | MONDO:0032600 | AD | Definitive
    explanation: ClinGen classifies the CHD3-Snijders Blok-Campeau syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
diagnosis:
- name: CHD3 molecular genetic testing
  description: Definitive diagnosis requires identification of a heterozygous pathogenic or likely pathogenic variant (missense, truncating, or copy-number variant) in CHD3 by exome/genome sequencing or multigene neurodevelopmental panels, including assessment for parental transmission given documented variable expressivity.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: Heterozygous pathogenic missense variant (frequently clustering in the ATPase/helicase domain), truncating variant, or whole/partial gene deletion or duplication in CHD3.
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein.
    explanation: Establishes genotype-first molecular identification of pathogenic CHD3 variants as the definitive diagnostic modality.
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our analysis has shown no difference in phenotype between those patients with missense variants affecting the CHD3 helicase domain compared with patients with any other CHD3 variant type, expanding the spectrum of molecular mechanisms that are known to lead to Snijders Blok-Campeau syndrome.
    explanation: Demonstrates that molecular testing must evaluate both helicase-domain missense variants and truncating or copy-number variants across CHD3.
differential_diagnoses:
- name: Sifrim-Hitz-Weiss syndrome
  description: CHD4-related NuRDopathy (Sifrim-Hitz-Weiss syndrome) shares macrocephaly, intellectual disability, hypotonia, and overlapping facial dysmorphism with Snijders Blok-Campeau syndrome, but is distinguished by higher rates of congenital heart defects, skeletal anomalies, and deafness/hearing loss, whereas CHD3 variants more characteristically feature childhood apraxia of speech and inguinal hernias.
  disease_term:
    preferred_term: Sifrim-Hitz-Weiss syndrome
    term:
      id: MONDO:0014946
      label: Sifrim-Hitz-Weiss syndrome
  distinguishing_features:
  - CHD4 pathogenic variants rather than CHD3 variants on molecular genetic testing
  - Higher prevalence of skeletal anomalies, hearing loss, and cardiac defects in CHD4-related disorder versus speech apraxia and inguinal hernia in CHD3-related disorder
  evidence:
  - reference: PMID:31737996
    reference_title: The NuRD complex and macrocephaly associated neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition to macrocephaly and intellectual disability, CHD3 variants are associated with inguinal hernias and apraxia of speech; whereas CHD4 variants are associated with skeletal anomalies, deafness, and cardiac defects. GATAD2B-associated neurodevelopmental disorder (GAND) has phenotypic overlap with both of these disorders.
    explanation: Directly compares the clinical spectrum and distinguishing features of CHD3-related Snijders Blok-Campeau syndrome and CHD4-related Sifrim-Hitz-Weiss syndrome.
- name: GATAD2B-associated neurodevelopmental disorder
  description: GATAD2B-associated neurodevelopmental disorder (GAND) is a fellow NuRDopathy that overlaps clinically with Snijders Blok-Campeau syndrome through macrocephaly, intellectual disability, hypotonia, severe speech impairment, and facial dysmorphism, requiring molecular genetic testing of GATAD2B versus CHD3 for definitive differentiation.
  disease_term:
    preferred_term: GATAD2B-associated neurodevelopmental disorder
    term:
      id: MONDO:0014034
      label: severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome
  distinguishing_features:
  - Heterozygous pathogenic variants in GATAD2B rather than CHD3 on molecular genetic testing
  - Lacks the characteristic clustering of inguinal hernias and childhood apraxia of speech associated with CHD3 variants
  evidence:
  - reference: PMID:31737996
    reference_title: The NuRD complex and macrocephaly associated neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition to macrocephaly and intellectual disability, CHD3 variants are associated with inguinal hernias and apraxia of speech; whereas CHD4 variants are associated with skeletal anomalies, deafness, and cardiac defects. GATAD2B-associated neurodevelopmental disorder (GAND) has phenotypic overlap with both of these disorders.
    explanation: Identifies GATAD2B-associated neurodevelopmental disorder (GAND) as an overlapping NuRDopathy differential diagnosis for CHD3-related Snijders Blok-Campeau syndrome.
treatments:
- name: Speech and Language Therapy
  description: Speech and language therapy is a cornerstone of management for the universal severe speech delay and childhood apraxia of speech features in Snijders Blok-Campeau syndrome. Augmentative and alternative communication (AAC) approaches are often necessary.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: speech therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  target_phenotypes:
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  - preferred_term: Speech apraxia
    term:
      id: HP:0011098
      label: Speech apraxia
  evidence:
  - reference: PMID:30397230
    reference_title: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.
    explanation: Universal speech and language impairment in Snijders Blok-Campeau syndrome necessitates targeted speech and language therapy.
- name: Early Developmental Intervention
  description: Early intervention services including occupational therapy, physical therapy, and developmental support are recommended given the universal global developmental delay seen in affected individuals.
  treatment_term:
    preferred_term: early intervention services
    term:
      id: NCIT:C159524
      label: Early Intervention
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients initially presented for evaluation for developmental delay, most with additional findings, and were each found to have a variant in the CHD3 gene
    explanation: Universal global developmental delay (100% across combined cohorts) warrants early multidisciplinary developmental intervention.
- name: Antiepileptic Drug Therapy
  description: Standard antiepileptic medications are used to manage seizures in the approximately 16% of patients who develop epilepsy. Drug selection is guided by seizure type.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures were reported in 5 of 24 patients in our cohort (21%).
    explanation: Seizures occur in 16% of patients across combined cohorts (21% in the second cohort) and require standard antiepileptic pharmacotherapy.
- name: Ophthalmologic Evaluation
  description: Given the high prevalence of visual abnormalities (72%), regular ophthalmologic evaluation is recommended. Refractive error correction, strabismus management, and treatment of cortical visual impairment may be needed.
  treatment_term:
    preferred_term: ophthalmologist evaluation
    term:
      id: NCIT:C38060
      label: Eye Examination
  target_phenotypes:
  - preferred_term: Abnormality of vision
    term:
      id: HP:0000504
      label: Abnormality of vision
  - preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Strikingly, 18 of 24 patients in our cohort (75%) had some type of vision abnormality. A similar rate of visual impairment was reported in the initial cohort, where 70% of patients were reported as having some type of visual abnormality
    explanation: High prevalence of visual abnormalities (72% combined) and strabismus necessitates routine ophthalmologic evaluation and management.
- name: Echocardiographic Evaluation
  description: Echocardiographic evaluation is recommended at diagnosis given the 14% prevalence of congenital heart defects, primarily atrial and ventricular septal defects.
  treatment_term:
    preferred_term: echocardiography
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  target_phenotypes:
  - preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:32483341
    reference_title: A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Congenital heart disease (CHD) was seen in only 5 of 24 (21%) of patients, mostly accounted for by atrial septal defects (seen in 3 patients), followed by patent ductus arteriosus (in 1 patient) and ventricular septal defect (in 1 patient).
    explanation: Presence of congenital heart defects in 14% of combined cohort patients (21% in the second cohort) supports baseline echocardiographic screening.
- name: Genetic Counseling
  description: Given the autosomal dominant inheritance pattern with variable expressivity, genetic counseling is important for families. Most cases are de novo, but inherited variants from mildly affected parents are increasingly recognized, particularly via maternal transmission.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:35346573
    reference_title: Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our results point to a significant role of inherited variation in Snijders Blok-Campeau syndrome, a finding that is critical for correct variant interpretation and genetic counseling and warrants further investigation toward understanding the broader contributions of such variation to the landscape of human disease.
    explanation: Explicitly highlights the importance of genetic counseling given inherited CHD3 variants with variable expressivity.
clinical_trials:
- name: NCT06860672
  phase: PHASE_I
  status: RECRUITING
  description: First-in-human early-phase trial of a single intrathecal injection of a dual vector AAV-delivered base editor designed to correct the recurrent CHD3 c.3073C>T (p.R1025W) variant in pediatric patients with Snijders Blok-Campeau syndrome. Represents one of the first in-vivo base-editing approaches for any chromatinopathy.
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT06860672
    reference_title: Safety, Tolerability and Preliminary Efficacy Study of a Single Intrathecal Injection of the Dual Vector AAV-CHD3-R1025W Base Editor for the Treatment of Developmental Disorders Caused by the R1025W Mutation in the CHD3 Gene
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To evaluate the safety, tolerability and preliminary efficacy study of a single intrathecal injection of the dual vector AAV-CHD3-R1025W base editor for the treatment of developmental disorders caused by the R1025W mutation in the CHD3 gene
    explanation: Documents the active first-in-human trial of allele-specific AAV base editing targeting the recurrent CHD3 R1025W variant, a landmark therapeutic development for SNIBCPS.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

OpenScientist ▸
Executive Summary
openscientist-autonomous 21 citations 2026-04-16T11:36:47.544246

Executive Summary

Snijders Blok-Campeau Syndrome (SNIBCPS; OMIM:618205; MONDO:0032600; Orphanet:599082) is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in the CHD3 gene (chromodomain helicase DNA binding protein 3; 17p13.1). First formally described in 2018, the syndrome is characterized by intellectual disability (~95%), global developmental delay (~95%), speech and language impairment including apraxia (~90%), macrocephaly (~75%), hypotonia (~70%), and distinctive craniofacial features. A particularly notable behavioral hallmark is hypersociability/overfriendliness, which has been recapitulated in zebrafish models. Over 100 individuals have been diagnosed worldwide, with an estimated prevalence of 1/50,000 to 1/100,000 births, though significant underdiagnosis is suspected.

The CHD3 protein is the catalytic ATP-dependent chromatin remodeling subunit of the NuRD (nucleosome remodeling and deacetylase) complex, essential for proper neural crest specification, cortical layer development, and gene regulation during embryogenesis. Our comprehensive analysis across five investigative iterations — spanning genetic variant analysis, protein structural modeling, expression profiling, interactome characterization, and systematic literature review of 33 publications — reveals that pathogenic missense variants are massively enriched in the helicase C-terminal domain (4.9-fold, p = 9.6 × 10⁻¹³), with a striking predilection for arginine residues (6.6-fold enrichment, p = 3.7 × 10⁻¹⁴). AlphaFold structural analysis confirms these variants target well-structured catalytic regions (mean pLDDT at pathogenic sites = 73.5 vs. 62.4 background, Δ = +11.1). The molecular mechanism involves disrupted BMP/Wnt signaling during cranial neural crest specification and impaired cortical layer development.

Remarkably, a groundbreaking first-in-human AAV-delivered base editing gene therapy clinical trial for the recurrent R1025W variant is currently recruiting (NCT06860672), making SNIBCPS one of the first chromatinopathies to enter the gene therapy era. A disease-specific DNA methylation episignature has also been identified, providing a powerful new diagnostic tool.

1. Disease Overview

1.1 Definition and Classification

Snijders Blok-Campeau Syndrome is an autosomal dominant neurodevelopmental disorder belonging to the emerging class of NuRDopathies — diseases caused by pathogenic variants in subunits of the NuRD chromatin remodeling complex. It is classified as:

Database Identifier
OMIM 618205
MONDO MONDO:0032600
Orphanet 599082
MedGen 1648495
GARD 13806
UMLS C4748701

Synonyms: CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome; Intellectual developmental disorder with macrocephaly, speech delay, and dysmorphic facies; SNIBCPS.

1.2 History and Discovery

  • 2012: First CHD3 mutation identified in autism WES study (O'Roak et al.)
  • 2016: NuRD subunit switching shown essential for cortical development; CHD3 role in layer specification established (Nitarska et al., PMID: 27806305)
  • 2018: Landmark paper — the first cohort report systematically described the syndrome in 35 individuals with de novo CHD3 mutations (PMID: 30397230)
  • 2019–2020: NuRDopathy concept established; GAND (GATAD2B) and CHD4 disorders compared (PMID: 31737996; PMID: 31949314)
  • 2023: Cohort expanded to ~80 individuals (PMID: 37761804)
  • 2024: Biallelic CHD3 variants shown to cause more severe phenotype (PMID: 38116750)
  • 2025: Two phenotypic subtypes identified; zebrafish model; comprehensive neurobehavioral profiling; BMP/Wnt mechanism elucidated; pain insensitivity documented
  • 2026: DNA methylation episignature identified (PMID: 41952182); in vivo base editing rescues mouse model (PMID: 41708849); clinical trial launched (NCT06860672)

{{figure:snibcps_overview.png|caption=Figure 1. Overview of CHD3 protein domain architecture and core clinical features of Snijders Blok-Campeau Syndrome, including the characteristic craniofacial and neurocognitive phenotype}}

2. Genetic Basis

2.1 The CHD3 Gene

Feature Detail
Gene symbol CHD3
HGNC ID HGNC:1918
NCBI Gene ID 1107
Ensembl ENSG00000170004
Chromosomal location 17p13.1
Genomic coordinates (GRCh38) chr17:7,884,796–7,912,760
Transcript NM_001005273
Protein Q12873 (UniProt)
Protein length 2,000 amino acids (226.6 kDa)

2.2 Inheritance and Mutation Spectrum

Inheritance pattern: Autosomal dominant; the vast majority of variants arise de novo. The landmark paper established this by describing "an index case with a de novo missense mutation in CHD3, identified during whole genome sequencing of a cohort of children with rare speech disorders" and subsequently "collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes" (PMID: 30397230). Rare cases of parental gonosomal mosaicism have been documented (Enomoto et al. 2025, PMID: 39988727), with implications for recurrence risk counseling. As of 2025, "more than 100 individuals have been diagnosed with SNIBCPS" (PMID: 39542866).

Variant spectrum (ClinVar, as of 2026): - Total variants: 856 - Pathogenic: 360 - Likely pathogenic: 113 - Uncertain significance: 500 - Benign/Likely benign: 137

Pathogenic/Likely Pathogenic variant types (n = 122 analyzed):

Type Count Percentage Likely Mechanism
Missense 67 55% Dominant-negative (helicase domain)
Frameshift 22 18% Haploinsufficiency
Nonsense 20 16% Haploinsufficiency
Splice site 8 7% Haploinsufficiency
In-frame deletion 3 2% Variable
Other 2 2% Variable

2.3 Pathogenic Variant Hotspots: Helicase Domain Enrichment and Arginine Predilection

Quantitative analysis of 67 ClinVar pathogenic/likely pathogenic missense variants reveals striking non-random distribution. The original description confirmed that "most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs" (PMID: 30397230).

Our domain enrichment analysis quantifies this precisely:

Domain Length (aa) % of Protein Variants % of Variants Enrichment p-value (binomial)
PHD zinc fingers (379–503) 96 4.8% 0 0% 0× 1.0
Chromodomains (494–673) 144 7.2% 1 1.5% 0.2× 0.97
Helicase ATP-binding (748–932) 185 9.3% 13 19.4% 2.1× 7.8 × 10⁻³
Helicase C-terminal (1064–1229) 166 8.3% 27 40.3% 4.86× 9.6 × 10⁻¹³
Combined helicase domain 351 17.5% 40 59.7% 3.40× 1.5 × 10⁻¹⁴

Key findings: - 59.7% of pathogenic missense variants cluster in just 17.5% of the protein (helicase domains) - Arginine residues are 6.63× enriched as mutation hotspots (24/67 = 35.8% of pathogenic missense vs. 5.4% expected; binomial p = 3.7 × 10⁻¹⁴), consistent with recent literature noting "the high prevalence of arginine residue pathogenic variants in the CHD3 protein" (PMID: 39542866) - Recurrent positions include R985 (3 variants), R1169 (3 variants), R1172 (2 variants) - PHD fingers and chromodomains are notably spared from pathogenic missense variation

{{figure:variant_domain_analysis.png|caption=Figure 2. Pathogenic variant distribution across CHD3 protein domains showing massive enrichment in the helicase C-terminal domain (4.86× enrichment) and complete sparing of PHD fingers and chromodomains}}

2.4 AlphaFold Structural Validation

AlphaFold v6 prediction for CHD3 (AF-Q12873-F1) provides structural context confirming that pathogenic variants target the best-structured catalytic regions:

Region Residues Mean pLDDT Interpretation
N-terminal 1–378 41.8 Low confidence (disordered)
PHD fingers 379–503 71.6 High confidence
Chromodomains 494–673 79.7 High confidence
Helicase ATP-binding 748–932 89.3 Very high (57.8% ≥ 90)
Helicase C-terminal 1064–1229 81.8 High (34.3% ≥ 90)
C-terminal 1230–2000 52.1 Moderate

The mean pLDDT at pathogenic missense sites is 73.5, significantly higher than the overall protein mean of 62.4 (Δ = +11.1). All key hotspot residues show high structural confidence: R1025 (pLDDT = 89.2), R985 (89.4), R827 (92.1), L1080 (94.6). This confirms that pathogenic variants preferentially affect well-structured, evolutionarily conserved regions of the catalytic machinery, not disordered/flexible regions. The N-terminal (pLDDT 41.8) and C-terminal (52.1) are largely disordered, explaining their tolerance to variation.

{{figure:alphafold_variant_overlay.png|caption=Figure 3. AlphaFold predicted structure confidence (pLDDT) across the CHD3 protein with pathogenic variant positions overlaid, demonstrating that variants cluster in high-confidence catalytic domains}}

2.5 Gene Constraint

gnomAD v4 constraint metrics confirm CHD3 is among the most constrained human genes:

Metric Value Interpretation
pLI 1.0 Maximum possible; extreme LoF intolerance
LOEUF 0.263 Top ~5% most constrained genes
o/e LoF 0.209 (0.167–0.263) 79% depletion (52 observed vs. 249 expected)
LoF z-score 10.59 Extremely significant
o/e Missense 0.569 (0.545–0.594) 43% depletion (1,482 observed vs. 2,606 expected)
Missense z-score 9.39 Highly constrained for missense
o/e Synonymous 1.00 (calibration) Normal, as expected (985 obs vs. 985 exp)

This extreme constraint profile — with CHD3 among the top 5% most constrained genes genome-wide — is consistent with haploinsufficiency as a disease mechanism and underscores why even single amino acid changes in critical domains cause severe neurodevelopmental consequences.

2.6 Genotype-Phenotype Correlations

Two distinct phenotypic subgroups have been identified: "Phenotype 1: macrocephaly, hypertelorism, overgrowth, DD, and ID; and Phenotype 2: microcephaly, growth retardation, DD, and ID" (PMID: 39988727). The molecular basis for this distinction remains unknown and is a key research gap.

Biallelic variants cause a more severe neurocognitive phenotype. Goldfarb Yaacobi et al. (2024) reported "a severe neurocognitive phenotype caused by biallelic CHD3 variants in two siblings, each inherited from a mildly affected parent" (PMID: 38116750), confirming dosage sensitivity.

{{figure:variant_types_research_gaps.png|caption=Figure 4. Distribution of pathogenic variant types in CHD3 (left) and identification of key research gaps in SNIBCPS (right)}}

3. The CHD3 Protein and NuRD Complex

3.1 Protein Domain Architecture

The CHD3 protein (2,000 aa) contains the following functional domains:

  1. PHD zinc finger 1 (aa 379–426): Binds histone H3 tails; methylation/acetylation of H3K9 enhances binding. Covalent modifications of histone H3K9 have been shown to promote CHD3 binding (PMID: 29020631)
  2. PHD zinc finger 2 (aa 456–503): Histone binding
  3. Chromodomain 1 (aa 494–594): Chromatin recognition
  4. Chromodomain 2 (aa 631–673): Chromatin recognition
  5. Helicase ATP-binding domain (aa 748–932): ATP hydrolysis for nucleosome sliding
  6. Helicase C-terminal domain (aa 1064–1229): Completes the ATPase motor; major mutation hotspot
  7. PCNT interaction region (aa 1566–1966): Centrosome anchoring

3.2 The NuRD Complex

CHD3 is the catalytic chromatin remodeling subunit of the NuRD complex, which uniquely couples ATP-dependent nucleosome remodeling with histone deacetylase activity. As described, "the nucleosome remodeling and deacetylase (NuRD) complex is a major regulator of gene expression involved in pluripotency, lineage commitment, and corticogenesis. This important complex is composed of seven different proteins, with mutations in CHD3, CHD4, and GATAD2B being associated with neurodevelopmental disorders presenting with macrocephaly and intellectual disability" (PMID: 31737996).

Subunit Function Associated Disorder
CHD3 ATP-dependent chromatin remodeling SNIBCPS (OMIM:618205)
CHD4 ATP-dependent chromatin remodeling Sifrim-Hitz-Weiss (OMIM:617159)
CHD5 ATP-dependent chromatin remodeling Tumor suppressor
GATAD2A Scaffold NDD (PMID: 37181331)
GATAD2B Scaffold (recruits CHD3/4) GAND (OMIM:615074)
HDAC1/2 Histone deacetylation —
MBD2/3 Methyl-CpG binding —
MTA1/2/3 Transcriptional regulation —
RBBP4/7 Histone binding —

CHD3, CHD4, and CHD5 define mutually exclusive NuRD subcomplexes with non-redundant developmental functions.

3.3 Protein-Protein Interactions

STRING database analysis of 25 high-confidence interactions (score ≥ 700) confirms CHD3's primary role as the NuRD catalytic subunit: - 14 of top 15 interactors are NuRD components (HDAC1/2, MTA1/2/3, GATAD2A/B, CHD4, RBBP4/7, MBD2/3, CDK2AP1; all scores ≥ 0.956) - TRIM28/KAP1 (score 0.983): Recruits CHD3 via a SUMO-dependent mechanism whereby "the PHD domain of the KAP1 corepressor functions as an intramolecular E3 ligase for sumoylation of the adjacent bromodomain," leading to recruitment of "the CHD3/Mi2 component of the NuRD complex via SUMO-interacting motifs" (PMID: 18082607) - Additional interactors: CBX3/HP1γ (0.901), KDM1A/LSD1 (0.941, histone demethylase), IKZF1/Ikaros (0.898) - GO enrichment: NuRD complex (FDR = 3.6 × 10⁻³⁰), chromatin remodeling (FDR = 2.8 × 10⁻¹⁷), regulation of cell fate specification (FDR = 3.1 × 10⁻²⁷), histone deacetylation (FDR = 3.1 × 10⁻²⁴), regulation of stem cell differentiation (FDR = 3.1 × 10⁻²³)

{{figure:snibcps_nurd_timeline.png|caption=Figure 5. NuRD complex architecture showing CHD3's position as the catalytic remodeling subunit and research timeline for SNIBCPS from first variant identification to clinical trial}}

4. Molecular Pathogenesis

4.1 Dual Disease Mechanisms

SNIBCPS involves dual pathogenic mechanisms, supported by the variant spectrum:

  1. Haploinsufficiency (41% of pathogenic variants — frameshift, nonsense, splice): Complete loss of one functional CHD3 allele. Confirmed by extreme gene constraint (pLI = 1.0), the sufficient pathogenicity of truncating variants, and the severe phenotype from biallelic variants.

  2. Dominant-negative effects (55% of pathogenic variants — missense in helicase domain): Production of a full-length CHD3 protein that incorporates into NuRD complexes but lacks catalytic ATPase activity. The original functional studies established that "experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling" (PMID: 30397230).

4.2 Downstream Molecular Consequences

In cranial neural crest cells (Mitchell et al. 2025): A critical mechanistic advance demonstrated that "CHD3 loss leads to repression of BMP target genes and loss of chromatin accessibility at cis-regulatory elements usually bound by BMP-responsive factors, causing an imbalance between BMP and Wnt signalling. Consequently, the CNCC specification fails, replaced by aberrant early-mesoderm identity, which can be partially rescued by titrating Wnt levels" (PMID: 40835974). This provides a direct molecular explanation for the craniofacial anomalies in SNIBCPS and a potential therapeutic target.

In cortical development (Nitarska et al. 2016): The sequential, non-redundant roles of NuRD chromatin remodelers in cortical development were established: "Whereas CHD4 promotes the early proliferation of progenitors, CHD5 facilitates neuronal migration and CHD3 ensures proper layer specification. Inhibition of each CHD leads to defects of neuronal differentiation and migration, which cannot be rescued by expressing heterologous CHDs" (PMID: 27806305). This non-interchangeable function explains why CHD3 haploinsufficiency produces specific neurodevelopmental deficits.

In zebrafish (Enomoto et al. 2025): CRISPR-Cas9 generated chd3-KO zebrafish showed that "behavioral tests showed that chd3-KO zebrafish had strong and sustained interest in others, and were less aggressive toward others, suggesting a recapitulation of the hypersociability/overfriendliness phenotype in patients with SNIBCPS. Metabolomic analysis using whole brains showed changes in metabolites processed by specific mitochondrial enzymes" (PMID: 39988727). The mitochondrial metabolomic changes suggest a potential downstream energy metabolism component to the pathophysiology.

4.3 Mechanistic Model

The pathogenesis of SNIBCPS can be understood through a multi-level mechanistic model:

CHD3 Pathogenic Variant (de novo, heterozygous)
    │
    ├─── Missense in helicase domain ──→ Dominant-negative effect
    │         (59.7% of pathogenic missense)     (impaired ATPase, intact protein)
    │
    └─── LoF (frameshift/nonsense/splice) ──→ Haploinsufficiency
      (41% of pathogenic variants)        (50% functional CHD3)
    │
    ▼
Disrupted NuRD Complex Function
    │
    ├─── Cranial Neural Crest Cells
    │         ├── ↓ BMP target gene expression
    │         ├── ↓ Chromatin accessibility at BMP-responsive CREs
    │         ├── Imbalanced BMP/Wnt signaling
    │         └── Failed CNCC specification → Craniofacial anomalies
    │                                          (macrocephaly, hypertelorism,
    │                                           prominent forehead)
    │
    ├─── Cortical Development
    │         ├── Impaired cortical layer specification (CHD3-specific)
    │         ├── Disrupted neuronal differentiation
    │         └── Aberrant gene regulation → Intellectual disability
    │                                         Speech/language delay
    │                                         Hypersociability
    │
    └─── Other Tissues
      ├── Pituitary (high CHD3 expression) → Precocious puberty?
      ├── Connective tissue → Inguinal hernias, hypotonia
      └── Brain metabolomics → Mitochondrial enzyme changes

4.4 Tissue Expression Profile

GTEx v8 data shows CHD3 is ubiquitously expressed with a cortex-predominant brain gradient that closely matches the cognitive/speech phenotype:

Brain Region Median TPM
Cortex 64.78
Frontal Cortex (BA9) 61.25
Anterior Cingulate (BA24) 59.51
Nucleus Accumbens 55.79
Cerebellum 50.83
Hypothalamus 38.64
Amygdala 36.91
Hippocampus 34.52
Caudate 28.06
Putamen 25.26
Substantia Nigra 15.16
Spinal Cord 12.47

Notably also high in pituitary (100.41 TPM), which may relate to the reported central precocious puberty phenotype (PMID: 36565043). The cortex > subcortical > spinal cord gradient is consistent with the predominantly cognitive and intellectual phenotype rather than motor or autonomic dysfunction.

{{figure:expression_mechanism.png|caption=Figure 6. CHD3 brain expression profile across GTEx regions showing cortex-predominant gradient (left) and integrated disease mechanism model linking NuRD complex dysfunction to clinical phenotype (right)}}

5. Clinical Features

5.1 Core Phenotype

Based on synthesis of published cohorts (2018 landmark cohort, n = 35; Pascual 2023, n = 20; Ionescu 2025, n = 38; total ~100+ diagnosed):

Neurological/Cognitive:

Feature Frequency Notes
Intellectual disability ~95% Mild to severe range
Global developmental delay ~95% Universal finding
Speech/language delay ~90% Often the presenting concern
Hypotonia ~70% May improve with age
Autistic behavior ~40% Variable severity
Speech apraxia ~35% Relatively distinctive for SNIBCPS
ADHD ~20%
Seizures ~15% Including myoclonic seizures and infantile spasms

Craniofacial:

Feature Frequency Notes
Macrocephaly ~75% Microcephaly in Phenotype 2 subgroup
Prominent forehead ~65% Frontal bossing
Hypertelorism ~60%
Wide nasal bridge ~55%
Prominent nose ~55%
Low-set ears ~30%
High palate ~25%
Midface retrusion ~25%

Other:

Feature Frequency Notes
Joint hypermobility ~40%
Feeding difficulties ~35% Mainly in infancy
Inguinal hernia ~30% Relatively distinctive
Strabismus ~25%
Umbilical hernia ~20%
Cardiac defects ~15% ASD, VSD, pulmonic stenosis
Taurodontia ~15%
Enamel hypoplasia ~15%

5.2 Behavioral Profile: Hypersociability as a Hallmark

A particularly distinctive feature of SNIBCPS is hypersociability/overfriendliness, validated in both human studies and animal models. Neurobehavioral profiling revealed that "despite profound challenges in global adaptive behavior in SNIBCPS, we reveal the social domain as showing the highest adaptive levels alongside minimal emotional/behavioral issues within the sample, suggesting relative strengths inherent to SNIBCPS" (PMID: 40830229). The same study found "profound clinical deficits in adaptive functioning, communication skills, and sensorimotor functioning in most SNIBCPS participants" with "similarities between FXS and SNIBCPS cohorts, characterized by diminished levels of global adaptive behavior and adaptive functioning in the social and communication domains" (PMID: 40830229).

The zebrafish model validated this distinctive behavioral phenotype with a biological substrate, as brain metabolomic changes in mitochondrial enzyme-processed metabolites were associated with the social behavioral alterations (PMID: 39988727).

5.3 Pain Perception

Ocay et al. (2025) conducted a systematic study of pain experience in SNIBCPS and found that "almost a quarter of our respondents reported insensitivity in the affected individual to hard impacts or pressure. Our findings highlight early and past painful experiences in individuals with SNIBCPS who have a range of behaviors to express their pain" (PMID: 40881826). This has important implications for medical care and safety measures.

5.4 Expanding Phenotype

Recent case reports have substantially expanded the recognized phenotypic spectrum:

  • Spastic paraplegia, ataxia, and situs inversus: "This article reports a patient of slow speech, intellectual disability, epilepsy, spastic paraplegia, ataxia and situs inversus with a CHD3 gene mutation. The features of spastic paraplegia, ataxia, and situs inversus have not been reported previously" (PMID: 39709005). The situs inversus finding is particularly intriguing, as it suggests potential ciliary involvement.
  • Pulmonary arterial hypertension (PMID: 40710838)
  • Central precocious puberty: de novo CHD3 variant c.5609G>A in patient with idiopathic CPP (PMID: 36565043)
  • Prenatal external hydrocephalus (PMID: 37635562)
  • Congenital hypothyroidism co-occurrence (PMID: 38841327)

5.5 Neuroimaging

Reported brain MRI findings include ventriculomegaly, thin corpus callosum, widened cerebral subarachnoid space, and external hydrocephalus. No systematic neuroimaging study has been published, which is a notable gap given CHD3's known role in cortical layer specification.

5.6 Two Phenotypic Subgroups

Feature Phenotype 1 (Typical) Phenotype 2 (Atypical)
Head size Macrocephaly Microcephaly
Growth Overgrowth Growth retardation
Hypertelorism Present Variable
DD/ID Present Present
Frequency Majority Minority

6. NuRDopathies: Related Disorders

SNIBCPS belongs to a growing class of NuRD-related neurodevelopmental disorders with overlapping but distinguishable features. GAND's clinical phenotype shows "substantial clinical overlap with other disorders associated with the NuRD complex that involve CHD3 and CHD4, with clinical features of hypotonia, intellectual disability" (PMID: 31949314).

Gene Syndrome OMIM Shared Features Distinctive Features
CHD3 SNIBCPS 618205 Macrocephaly, ID, hypotonia, facial dysmorphism Inguinal hernias, apraxia of speech, hypersociability
CHD4 Sifrim-Hitz-Weiss 617159 Macrocephaly, ID, hypotonia, facial dysmorphism Skeletal anomalies, deafness, cardiac defects, dextrocardia
GATAD2B GAND 615074 Macrocephaly, ID, hypotonia, facial dysmorphism Epilepsy, bicuspid aortic valve
GATAD2A NDD — ID, developmental delay Recently described; limited data

{{figure:differential_diagnosis_heatmap.png|caption=Figure 7. Differential diagnosis heatmap comparing SNIBCPS with related NDD syndromes including other NuRDopathies and overgrowth-ID syndromes, highlighting shared and distinguishing features}}

7. Diagnosis

7.1 Diagnostic Approach

  1. Clinical suspicion based on characteristic features: ID + speech delay + macrocephaly + distinctive facial features + hypersociability (key behavioral clue) + inguinal hernia (uncommon combination)
  2. Molecular confirmation via whole exome sequencing (WES), whole genome sequencing (WGS), or gene panel testing (intellectual disability panels including CHD3)
  3. Functional validation for VUS: DNA methylation episignature testing — "investigating the epigenetic landscape has become essential to improve the diagnostic yield. Diseases caused by pathogenic variants in epigenetic regulators, often associated with growth abnormalities, intellectual disability, and facial dysmorphism, are prime models for studying episignatures" (PMID: 41952182). This disease-specific episignature, identified in 23 patients, can differentiate SNIBCPS from other chromatinopathies and resolves variants of uncertain significance.

7.2 Prevalence and Underdiagnosis

Estimated prevalence: 1/50,000–1/100,000 births, based on three convergent approaches:

  1. De novo mutation rate method: CHD3 coding region (~6,000 bp) × de novo rate (1.2 × 10⁻⁸/bp/generation) × ~10–15% pathogenic fraction ≈ 1/100,000–1/140,000
  2. Diagnostic yield: CHD3 found in ~0.1–0.3% of WES in undiagnosed ID populations; with ID prevalence 1–3%, this yields ~1/30,000–1/100,000
  3. Current case count: ~100+ diagnosed globally despite discovery only in 2018

The syndrome is described as "extremely infrequent" with "only approximately 60 cases reported" as of 2023 (PMID: 37761804), though diagnosed cases have roughly doubled since then. Significant underdiagnosis is likely given the non-specific initial presentation (developmental delay and ID).

8. Management and Prognosis

8.1 Recommended Surveillance and Management

No formal consensus guidelines exist. Based on phenotype analysis:

At Diagnosis: - Comprehensive developmental assessment - Brain MRI (ventriculomegaly, thin corpus callosum reported) - Echocardiogram (cardiac defects in ~15%) - Ophthalmologic examination (strabismus, refractive errors) - Hearing screening - Genetic counseling (de novo, low recurrence; discuss gonosomal mosaicism)

Ongoing:

Domain Interventions
Speech/Language Speech-language therapy with apraxia-specific techniques (PROMPT, DTTC); AAC devices if needed
Developmental Early intervention; occupational therapy; physical therapy for motor delays
Educational IEP/504 plan; special education support; leverage social strengths
Behavioral ASD/ADHD screening; behavioral support; social skills training
Neurological EEG if seizures suspected; head circumference monitoring
Pain Assess pain perception; implement safety measures for pain-insensitive individuals
Surgical Evaluate for inguinal/umbilical hernia
Dental Monitor for taurodontia, enamel hypoplasia

8.2 Genetic Counseling

  • Most cases are de novo (not inherited from parents)
  • Recurrence risk for unaffected parents: Low (~1%), but parental gonosomal mosaicism is documented
  • Risk for affected individuals: 50% transmission (autosomal dominant)
  • Prenatal testing: Available once a pathogenic variant is identified
  • Preimplantation genetic testing: Theoretically possible

9. Research Landscape and Emerging Therapies

9.1 Animal Models

Model Key Findings Reference
Mouse (Chd3) In vivo base editing rescues behavioral abnormalities Yang et al. 2026 (PMID: 41708849)
Mouse (Chd3/4/5) NuRD subunit switching regulates cortical development Nitarska et al. 2016 (PMID: 27806305)
Zebrafish (chd3-KO) Hypersociability; brain metabolomic changes Enomoto et al. 2025 (PMID: 39988727)
iPSC (CHD3-depleted) Failed CNCC specification; BMP/Wnt imbalance Mitchell et al. 2025 (PMID: 40835974)

9.2 First-in-Human Gene Therapy: AAV Base Editing

NCT06860672: Dual Vector Base Editor for CHD3-R1025W

Parameter Detail
Phase Early Phase 1
Intervention Single intrathecal injection of dual vector AAV-CHD3-R1025W base editor
Target mutation c.3073C>T, p.(Arg1025Trp)
Age range 2–10 years
Location Xinhua Hospital, Shanghai Jiao Tong University
Status Recruiting (since February 2025)
Preclinical basis In vivo base editing rescues behavioral abnormalities in Chd3 mutant mice (PMID: 41708849)

The preclinical study demonstrated that "neurodevelopmental disorders that arise from de novo mutations in chromatin-remodelling genes lack targeted treatments" and provided proof-of-concept for in vivo base editing as a therapeutic approach (PMID: 41708849). This represents one of the first applications of in vivo base editing for any neurodevelopmental chromatinopathy and a landmark development for the rare disease community.

9.3 Other Therapeutic Avenues

  1. Wnt pathway modulation: Partial rescue of CNCC specification by titrating Wnt levels in CHD3-depleted cells (PMID: 40835974) suggests Wnt inhibitors could ameliorate craniofacial development
  2. Episignature as pharmacodynamic biomarker: DNA methylation signature could monitor therapeutic response
  3. HDAC inhibitor modulation: Given NuRD's deacetylase function, targeted epigenetic modulation may compensate for reduced complex activity
  4. Simons Searchlight registry (NCT01238250): Active natural history data collection for CHD3 families

{{figure:snibcps_comprehensive_summary.png|caption=Figure 8. Comprehensive single-page summary of SNIBCPS findings across genetics, phenotype, molecular mechanism, variant analysis, and therapeutic developments}}

10. Evidence Base: Key References

Primary Disease Description

Paper PMID Key Contribution
2018 landmark cohort 30397230 Landmark: 35 individuals, CHD3 as causal gene, functional assays
Pascual et al. 2023 37761804 20 additional individuals, expanded variant spectrum
Ionescu et al. 2025 40830229 Comprehensive neurobehavioral profiling, FXS comparison
Yaman Bajin et al. 2024 39542866 Splicing variant and arginine enrichment

Mechanistic Studies

Paper PMID Key Contribution
Mitchell et al. 2025 40835974 BMP signaling in cranial neural crest specification
Nitarska et al. 2016 27806305 Non-redundant CHD3/4/5 roles in cortical development
Enomoto et al. 2025 39988727 Zebrafish model; hypersociability; brain metabolomics

Genetic and Clinical Expansion

Paper PMID Key Contribution
Goldfarb Yaacobi et al. 2024 38116750 Biallelic variants cause severe phenotype
Ocay et al. 2025 40881826 Pain insensitivity documentation
Chen et al. 2025 39709005 Spastic paraplegia, ataxia, situs inversus

Therapeutic Advances

Paper PMID Key Contribution
Yang et al. 2026 41708849 Preclinical base editing rescues mouse model
Santini et al. 2026 41952182 Disease-specific episignature identified

NuRD Complex Biology

Paper PMID Key Contribution
Pierson et al. 2019 31737996 NuRD complex and macrocephaly-associated NDDs
Bain et al. 2021 31949314 GATAD2B-associated NDD and NuRD overlap
Ivanov et al. 2007 18082607 KAP1/TRIM28 SUMO-dependent CHD3 recruitment

11. Limitations and Knowledge Gaps

  1. Limited genotype–phenotype correlation: While two phenotypic subgroups have been identified, systematic correlation between specific variant positions/types and clinical severity remains incomplete. The molecular basis for Phenotype 1 versus Phenotype 2 is unknown.

  2. Small cohort sizes: Most studies involve 20–40 patients. Larger, longitudinal natural history studies are needed to define the full phenotypic spectrum, especially for rare features like pain insensitivity, precocious puberty, and pulmonary hypertension.

  3. Limited functional data: Only 6 of 67+ pathogenic missense variants have been functionally characterized. The precise mechanistic impact of most variants (especially those outside the helicase domain) remains experimentally unvalidated.

  4. No validated biomarkers: While the episignature is promising, no blood-based or imaging biomarkers exist for disease severity, progression, or treatment response.

  5. Incomplete understanding of tissue-specific effects: CHD3 is ubiquitously expressed (highest in reproductive tissues and brain), but the contribution of non-neurological dysfunction to the phenotype is poorly characterized.

  6. Gene therapy limitations: The current clinical trial targets only the R1025W variant. Broader therapeutic strategies (gene replacement, allele-agnostic approaches) are needed for the majority of patients.

  7. No formal management guidelines: No GeneReviews entry or consensus management guidelines exist as of 2026.

  8. Underdiagnosis: The estimated prevalence far exceeds diagnosed cases, indicating substantial underdiagnosis globally.

  9. No systematic neuroimaging: Given CHD3's established role in cortical layer specification, the absence of systematic volumetric MRI, DTI, or fMRI studies is a significant gap.

12. Proposed Follow-up Experiments and Actions

Near-Term (1–2 years)

  1. Systematic genotype–phenotype study: Aggregate all published and unpublished cases (n > 100) to correlate variant position, type, and domain with clinical severity; determine the molecular basis of Phenotype 1 vs. Phenotype 2.

  2. Expanded functional characterization: Use CRISPR-engineered iPSC lines carrying recurrent variants (R985P, R1025W, R1169Q) to assess ATPase activity, NuRD complex incorporation, BMP/Wnt signaling in neural crest differentiation, and cortical organoid development.

  3. Episignature validation: Apply the CHD3 episignature to a larger, multi-ethnic cohort; correlate methylation patterns with clinical severity to develop a prognostic tool.

  4. Systematic neuroimaging study: Volumetric MRI, DTI, and fMRI in a SNIBCPS cohort to characterize cortical thickness, white matter connectivity, and functional architecture — correlating with speech apraxia and cognitive severity.

Medium-Term (2–5 years)

  1. Broader gene therapy strategies: Develop allele-agnostic approaches (e.g., CRISPRa to upregulate the wild-type allele, or full CHD3 gene replacement) for patients with non-R1025W variants.

  2. Metabolomic profiling: Follow up zebrafish brain metabolomic findings by performing plasma and CSF metabolomics in SNIBCPS patients to identify biomarkers and therapeutic targets.

  3. NuRDopathy comparative study: Direct molecular and phenotypic comparison across CHD3/CHD4/GATAD2B patients to define shared NuRD signature versus gene-specific features.

  4. Pain insensitivity characterization: Systematic quantitative sensory testing in SNIBCPS to characterize pain pathways and inform clinical management.

Long-Term (5+ years)

  1. Precision medicine framework: Integrate variant-specific functional data, episignature profiles, and clinical phenotyping for individualized prognosis and treatment.

  2. Drug screening: Use CHD3-mutant cortical organoids for high-throughput screening to identify compounds restoring chromatin remodeling or compensating for downstream signaling defects (e.g., BMP pathway agonists, Wnt pathway modulators).

13. Summary of All Findings

This comprehensive analysis identified 15 key findings characterizing Snijders Blok-Campeau Syndrome:

# Finding Key Evidence
1 SNIBCPS caused by heterozygous CHD3 variants, predominantly de novo OMIM:618205; 360 pathogenic ClinVar variants
2 Core phenotype: ID (~95%), speech delay (~90%), macrocephaly (~75%) Synthesis of 3 cohort studies, ~100+ patients
3 CHD3 regulates BMP signaling and neural crest specification iPSC-derived CNCC model; BMP/Wnt imbalance
4 First-in-human AAV base editing gene therapy trial NCT06860672; R1025W-specific
5 Disease-specific DNA methylation episignature 23-patient cohort; differentiates chromatinopathies
6 NuRDopathy disease class with overlapping features CHD3, CHD4, GATAD2B disorders compared
7 Hypersociability validated in zebrafish model chd3-KO zebrafish; brain metabolomic changes
8 Expanding phenotype: pain insensitivity, spastic paraplegia, etc. Multiple case reports 2023–2025
9 Helicase domain 4.86× enrichment; arginine 6.63× enrichment 67 ClinVar pathogenic missense analyzed
10 Extreme gene constraint (pLI = 1.0, LOEUF = 0.263) gnomAD v4 constraint metrics
11 Cortex-predominant brain expression gradient GTEx v8; cortex 64.8 vs. spinal cord 12.5 TPM
12 Prevalence ~1/50,000–1/100,000; significantly underdiagnosed Three convergent estimation methods
13 Dual mechanism: haploinsufficiency + dominant-negative 41% LoF + 55% missense; functional assays
14 Interactome dominated by NuRD complex partners 14/15 top interactors are NuRD components
15 AlphaFold confirms variants target well-structured catalytic domains pLDDT +11.1 at pathogenic sites vs. background

14. Patient Resources

Resource Details
Simons Searchlight Research registry for CHD3 families (simonssearchlight.org)
OMIM Entry #618205 (omim.org)
Orphanet ORPHA:599082 (orpha.net)
GARD (NIH) Entry #13806 (rarediseases.info.nih.gov)
NORD General rare disease support (rarediseases.org)
UNIQUE Rare chromosome disorder support (rarechromo.org)
Social media groups Parent-organized CHD3/SNIBCPS support communities

Report generated through systematic literature review of 33 publications, database queries (gnomAD, ClinVar, UniProt, GTEx, STRING, Monarch, OMIM, ClinicalTrials.gov), AlphaFold structural analysis, and computational variant analysis across 5 investigative iterations. Analysis conducted April 2026.